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Methodological statistical analysis is a necessary beginning of any study of this sort
if the study is to be scientiﬁcally enlightening.
But it is not the end;
it will have to be subject to judgements based on knowledge of the material
that goes beyond the purely statistical analysis
in this study as in all others.
JOSEPH BERKSON, 1942
Abstract
The overarching aim of this work has been to develop and apply statistical methods for es-
timating cancer patient survival from population-based register data. Particular focus has been
on statistical methods that can be used for presenting cancer survival statistics from adminis-
trative health data registers in a manner that is relevant for physicians and patients.
Study 1: In this study we clarify and discuss the relative merits of estimates of crude and net
cancer patient survival, respectively. In addition, we demonstrate how period analysis, applied
in a competing risks setting, can be utilised to predict crude survival probabilities applicable to
newly diagnosed cancer patients. As a motivating clinical example, we use data from the Na-
tional Prostate Cancer Register to assess the impact of prognostic factors on the risk of prostate
cancer death in relation to death from other causes than prostate cancer, and event-free survival,
among recently diagnosed patients. We conclude that the period estimates of crude survival
oﬀer a useful basis for risk communication between physicians and clinicians and advocate their
use as means to answer prognostic questions.
Study 2: Late adverse health eﬀects in cancer patients are a growing problem given the longer
survival seen for most cancers. Deaths that occur as a consequence of treatment toxicity can
be regarded as indirect deaths due to cancer. In this methodological study we extend ﬂexi-
ble parametric survival models for relative survival by partitioning the overall excess mortality
from cancer into two component parts; excess mortality from diseases of the circulatory system,
DCS, (assumed caused by the treatment), and remaining excess cancer mortality. We present
summary measures for quantifying the risk for death from late eﬀects of treatment relative to
the overall risk of dying of breast cancer, or causes unrelated to the cancer. The method is
illustrated using data obtained from the Swedish Cancer Register on women diagnosed with
breast cancer in Sweden between 1973 and 1992.
Study 3: Survival after Hodgkin lymphoma has increased substantially in the past four decades,
following the development of eﬀective multi-agent chemotherapy, introduction of combined-
modality therapy with reductions in radiation ﬁeld size and dose, and more apt evaluation of
treatment response. The aim of this study was to present clinically interpretable estimates of
temporal trends in the burden of fatal excess DCS mortality among Hodgkin lymphoma sur-
vivors who were treated in the 1970's through 1990's, and to predict the future clinical burden
among patients diagnosed more recently. Using data from the Swedish Cancer Registry we
showed how the excess DCS mortality, within 20 years after diagnosis, has decreased continu-
ally since the mid-1980s and is expected to further decrease among patients diagnosed in the
modern era. However, when accounting for competing causes of death, we found that excess
DCS mortality constitutes a relatively small proportion of the overall mortality among Hodgkin
lymphoma patients in Sweden.
Study 4: In this study we show how recently developed ﬂexible parametric cure models, com-
bined with competing risks theory, can be used to estimate crude probabilities that cancer
patients who are alive will eventually die from their cancer, or from other causes, respectively.
Moreover, we show how to 'update' the prognosis for patients who have survived some time after
their diagnosis via the use of conditional probabilities. The method is discussed and demon-
strated using data from the Swedish Cancer Register on patients diagnosed with melanoma,
colon cancer and acute myeloid leukemia between 1973 and 2007.
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List of abbreviations
The following abbreviations are used throughout this thesis:
S(t) All-cause survival
S∗(t) Expected all-cause survival in a population assumed free from the disease under study
R(t) Relative survival
h(t) All-cause hazard
hc(t) Cause-speciﬁc hazard
h∗(t) Expected hazard in a population assumed free from the disease under study
λ(t) Excess hazard
H(t) Cumulative all-cause hazard
H∗(t) Cumulative expected hazard
Λ(t) Cumulative excess hazard
Fc(t) Cause-speciﬁc cumulative distribution function
Crc(t) Crude probability of death from the diagnosed cancer
Cro(t) Crude probability of death from causes other than the diagnosed cancer
Cralive,c(t) Crude probability of being alive and predicted to die from the diagnosed cancer
Cralive,o(t) Crude probability of being alive and predicted to die from causes other than the diagnosed
cancer
pi Cure proportion
Pbtd,c Proportion of personally cured patients
CDR Cause of Death Register
ICD International Classiﬁcation of Diseases
INCA Information Network for Cancer Care
NPCR National Prostate Cancer Register
PSA Prostate Speciﬁc Antigen
RCC Regional Cancer Center
SCR Swedish Cancer Register
TNM Tumor, Node, Metastasis
HMD Human Mortality Database
1 Introduction
In Sweden, the collection of individual-speciﬁc data in population-based health registers has been
routine for more than half a century. Consequently, register-based research has become an integral
part of the Swedish epidemiological research tradition. It is not surprising that continuous eﬀorts
are made to nurture this tradition, and to push the limits for how health registers are used in
research [1]. As we broaden the focus from classical epidemiological studies, to include also more
complex clinical research studies, we need to continue developing appropriate statistical methods
to ensure that maximum use is made of the data at hand. We must also realize that the tools
we develop for this purpose are typically not self-explanatory, and that considerable eﬀort must be
made to communicate new methods and make them accessible and understandable for their target
users.
Cancer statistics have a broad range of consumers, ranging from researchers, physicians, patients,
patient organisations, policymakers to medical (as well as non-medical) journalists. Although many
of the classical methods for producing and presenting statistics of cancer patient survival are useful
for aetiological and public health research, they may be less optimal for communication in a clinical
setting. For example, the most commonly reported statistics for population-based cancer patient
survival, relative survival, is interpreted in the hypothetical scenario where cancer is the only possible
cause of death. From the perspective of newly diagnosed patients, who seek to understand the
potential impact of the cancer diagnosis on their life expectancy, such statistics may be of little help.
Ideally, clinically relevant statistics on prognosis of cancer patients should enhance the information
present in the data, be presented in a manner that can aid physicians in risk counselling situations,
and facilitate informed decisions about the clinical management of cancer patients. Even though
statistical methodology that aims to fulﬁl this purpose is regularly developed, the uptake of the new
statistical theory to applied research in a broad sense is typically slow. The reason for this is most
likely multi-factorial but possible explanations include:
• new statistical theory does not always reach audiences beyond the technical journals where
the method was ﬁrst published
• a lack of a clear link between the applied research question and the new statistical theory
• the new methodology is not implemented in statistical software used by applied researchers
• an unwillingness among applied researchers to abandon traditional, and widely accepted sta-
tistical methods (old habits are hard to kick!)
This thesis strives to overcome some of these barriers by combining the development of new
statistical theory, needed to appropriately answer clinical research questions, with illustrative ex-
amples of the methods using real data. Crucial to this endeavor has also been to motivate and
disseminate non-standard statistical methods to their target audiences by providing easy access via
1
implementation of the methods in user-friendly software, teaching short courses, and by publishing
educational scientiﬁc papers in epidemiological and clinical journals.
2
2 Aims of the thesis
The overall aim of this research is to develop statistical methods for estimating and modelling cancer
patient survival, with particular emphasis on developing and applying new methods for presenting
population-based cancer survival statistics in a manner relevant for physicians and patients.
Speciﬁcally, the aims were to:
• Appraise statistical methods for competing risks in a population-based setting and to discuss
interpretation, assumptions, strengths and weaknesses in relation to other, more traditional
statistical methods for population-based cancer patient survival (Study I).
• Extend ﬂexible parametric survival models, adapted for relative survival, in order to estimate
treatment-related mortality in the presence of competing risks (Studies II and III).
• Combine the use of ﬂexible parametric cure models with competing risks theory in order to
estimate the proportion of patients not bound to die from their diagnosed cancer (Study IV).
• Demonstrate how period analysis and conditional estimates of survival can be applied in
combination with the proposed statistical methods to increase the usefulness of the results for
newly diagnosed cancer patients (Studies I and IV).
• Implement the developed statistical methodology in user-friendly software to make it readily
available to applied users (Studies II and IV).
3
3 Background
3.1 Cancer
The human body consists of 100 trillion (1014) cells. These are classiﬁed into over 200 distinct
cell types, where each type has a specialised task to perform. Cancer is the shared name for
diseases that can arise in almost any of the diﬀerent cell types. As such, cancer is not one but
many diﬀerent diseases. The main characterising features of carcinogenesis, i.e., the process that
transforms healthy cells into cancer cells are, uncontrolled proliferation (destabilised cell division),
dediﬀerentiation (loss of specialisation), impaired ability to undergo normal apoptosis (programmed
cell death), acquired autonomy from other cells (self-suﬃcient in growth signals and blood supply),
and loss of capacity to repair genetic errors [2]. The reprogramming of cells occurs as a consequence
of genetic mutations and epigenetic changes in healthy cells. Whilst reprogramming of one single
healthy cell into a cancer cell is suﬃcient to give rise to cancer, several changes to the genetic material
of healthy cells are required to initiate and promote a malignant transformation. In most cases, the
process in which one single ancestral cancer cell develops into detectable cancer takes many years,
although the natural history of cancer varies heavily across diﬀerent cancer types. Unless the disease
is successfully treated or controlled, cancer might spread via the blood and lymphatic system and
invade other organs of the body by forming metastases. Treatment options for most cancers include
removal of solid tumours by surgery, targeting rapidly dividing cells with chemotherapy, shrinking
tumours and destroying cancer cells by radiation, blocking the growth of cancer cells by targeted
therapies, or inducing the patient's own immune system by immunotherapy. The aim (curative or
palliative) and choice of treatment depends on the type, location and spread of the disease, as well
as on the health status of the patient. Metastasized cancer is, for example, generally not amenable
to cure, and the treatment is thus primarily palliative.
Cancer is generally regarded as a chronic disease. As such, it is a huge burden on our society,
both economically and socially. Annually, more than 50,000 new cases are diagnosed in Sweden,
and approximately 20,000 deaths from cancer occur [3]. About 50% of all new cases occur in
individuals older than 70 years, and one third of the population will be diagnosed with cancer
before their 75th birthday [3]. The number of individuals who live with cancer has increased over
time, and is estimated to further increase in the future as many types of cancer can be detected at an
earlier stage than before, and treatment regiments are becoming increasingly successful. Moreover,
the age structure in Sweden is changing with the population aging [4]. The growth of the elderly
population and the increase in the proportion in older age groups, further adds to the cancer burden
and resources that are used for cancer care. In addition, the social consequences stretch beyond
the individuals who are personally aicted by cancer since virtually everyone will have an aﬀected
family member or friend at some time during their lives.
The known causes of cancer can be divided into heritable factors, life-style factors, reproductive
factors, infectious agents, exposure to radiation (ionising and non-ionising ultraviolet radiation),
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workplace/household carcinogens and pollution. Lifestyle factors such as smoking, diet, and physical
activity are estimated to cause about 70% of all cancers [5]. Smoking alone is believed to be
attributable to 15% of all cancers, whereas heritable factors give rise to approximately 5 to 10% of
all cases [5].
3.2 The role of a cancer registry in cancer control
The Swedish Cancer Registry was founded in 1958 with the purpose of creating a data base with
national coverage that could be used to map the occurrence of cancer, monitor temporal changes
in incidence, mortality and survival, facilitate clinical and epidemiological research and make inter-
national comparisons possible [6]. This role has remained virtually unchanged until today although
organisational changes for oncologic care in Sweden have led to the majority of the registration
work and activities related to cancer control now taking place in Regional Cancer Centers. Cancer
registries have an important role in cancer control programmes. As deﬁned by the World Health
Organisation [7],
"a national cancer control programme is a public health programme designed to reduce the number
of cancer cases and deaths and improve quality of life of cancer patients, through the systematic
and equitable implementation of evidence-based strategies for prevention, early detection, diagnosis,
treatment, and palliation, making the best use of available resources."
Classic components of a cancer control programme include activities related to 1) primary preven-
tion, 2) screening, 3) enabling early diagnosis, 4) optimisation of treatment, 5) rehabilitation, and
6) palliative care [8]. Cancer registries have a unique role in these activities since their wealth of
data can be used in research that monitors and evaluates the performance of existing programmes,
as well as to carry out needs assessment for future programmes [9, 8, 10]. From an international
perspective, no cancer registry is currently involved in each and every component of cancer con-
trol. Like in society at large, resources are limited and the goals and tasks in an organisation are
balanced against their beneﬁts and their costs. For cancer registries, the implication is that their
direct role in cancer control is somewhat fragmented. In a survey of the members and associate
members of the International Association of Cancer Registries (IACR), Armstrong reviewed what
activities (related to cancer control) that cancer registries worldwide were most frequently involved
in. Most contributions were in basic research on cancer prevention (epidemiological research into
the causes of cancer), clinical trials of treatment, and the production of incidence statistics. Other,
less commonly, reported activities were related to situation analysis, coordination and monitoring
of screening programmes, and public education [8]. In practice, many external organisations and
research groups also contribute to the various parts of cancer control by using registry data for aeti-
ological research, evaluation of primary and secondary prevention programmes, health care planning
and patient care. In such situations the cancer registry does not participate directly in the research
and surveillance activities, but serves as the collector and provider of research data.
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3.3 Outcome measures used in cancer control
The statistical measures that are typically used in cancer control include incidence, mortality and
survival [11]. Incidence is the most frequently reported measure of cancer burden. Trends in
incidence, i.e., the rate at which new cancer cases arise in a given population, mimics trends in the
distribution of risk factors and can therefore be used to monitor the performance of eﬀorts that
have been taken to prevent disease occurrence (i.e., activities related to primary prevention).
Mortality reﬂects death in the population and is the principal outcome measure for evaluating
the success of screening programs. Mortality is calculated by dividing the number of deaths from
cancer by the total population at risk of dying over some well-deﬁned time period. As such, trends
in mortality are not only mimicking trends in cancer survival but also trends in the incidence. The
accuracy of mortality statistics is closely linked to the accuracy of the causes of death reported on
death certiﬁcates [12].
To evaluate changes in the progress of diagnosing and eﬀectively treating cancer patients, estimates
of survival (or equivalently, mortality restricted to the population of cancer patients) is the most
appropriate measure. Calculation of survival requires patient follow-up (from the date of diagnosis
until death or censoring) and provides an estimate of the proportion of patients who are still alive
as a function of time since their diagnosis. Survival is the cornerstone of all studies included in this
thesis and we will return to the topic of estimation and interpretation of survival in the coming
chapters.
In addition to incidence, mortality and survival, other useful measures include prevalence, and
person-years of life lost due to cancer. Common for all measures introduced here is that none take
into account the morbidity that patients might suﬀer from their disease. Quality of life adjusted
outcome measures are needed to fully account for all components of cancer control but a detailed
review of this aspect of patient care is beyond the scope of this thesis.
3.4 Communicating and producing statistics relevant for clinicians and patients
Whilst all of the above mentioned outcome measures have an important role in cancer control, their
usefulness is limited for an individual patient, whose primary interest might be in understanding
how the disease, and the treatment of it, will aﬀect her life. Psychosocial aspects, such as feelings
of guilt, anxiety and fear, have long been recognised as important issues in cancer patient care, but
patient reactions to cancer are not only highly variable between individuals, but also during diﬀerent
phases of disease. The coping strategy for one patient might be to actively seek information about
the disease, in order to gain an understanding of the severity of the situation and the expected
course of treatment, whereas another patient might prefer taking a more passive role. In many
countries, including Sweden, the general idea in patient education and rehabilitation activities is
that an active role, that involves confronting facts about the disease and, if possible, participating
in decisions about the management and care, is more beneﬁcial for the patients than a passive role
[13]. However, adjusting to a life as a cancer patient is a long process, that often starts in a state
6
of shock and includes disease reaction, anxiety management, reality adjustment, and eventually
ﬁnding a way back to everyday life. It is important to respect that not all patients are ready to
take an active role during all phases of this process.
Risk counselling lays the foundation for the information and tools that patients require in order to
become active participants. It involves disseminating the most recent information about cancer risk
and prognosis from the learning continuum of research, via health care professionals, to cancer pa-
tients and their families. The general idea behind any form of risk counselling is to provide patients
with a sense of coherence and encourage informed participation in medical care. The success of risk
counselling is, nevertheless, highly dependent on the communication skills and information literacy
and numeracy of both the counsellor and counselee, as well as the understanding of the source data
that forms the basis for the information [14].
This thesis is concerned with producing statistics that are useful to predict and summarise the most
likely outcome of the disease. There is no standardised way in which such information is commu-
nicated between clinicians and patients today, and there is not even agreement that information
that stems from grouped patient data should be presented and discussed routinely with patients.
Notwithstanding this, it is recommended that an explicit wish from the patient to discuss the antici-
pated prognosis, and the potential risks and beneﬁts of the treatment, in terms of actual percentages
should be respected [15]. At ﬁrst glance, estimates of survival seem to be the most suitable outcome
measure to attempt to answer such questions, and in practice, the ﬁve-year survival probability is
often reported and quoted as a measure of prognosis. There are however, several pitfalls with a
naive use of survival proportions in risk counselling between physician and patient which leave room
for misuse and misinterpretation.
Firstly, the estimated proportion of patients who survive an arbitrary number of years after their
initial cancer diagnosis is typically calculated by the use of explicit information about the recorded
cause of death, or via a relative survival framework. Both these approaches aim to estimate net
survival. As such, the correct interpretation of, for example, the ﬁve-year cancer speciﬁc survival
proportion is: "the proportion of patients who survived ﬁve years after their diagnosis under the as-
sumption that only the diagnosed cancer could kill them." The subtle assumption that the patients
are assumed immune from competing causes of death is often not fully understood and therefore
sometimes over-looked in the communication of survival statistics in the context of cancer prognosis.
Secondly, communicating the relevant time frame for which survival statistics are valid is crucial. A
statement like "The survival of patients with similar disease and patient characteristics as you has
been reported to be around 70%" can be grossly misleading since it entirely lacks references to time.
Does it suggest that 70% will not die from the cancer within a speciﬁc time window after diagnosis
(e.g., 5 years), or perhaps that 70% of the patients will never die from the diagnosed cancer? What
if the patient has already survived one year since the diagnosis? How does that fact alter the above
statement? Moreover, from what cohort of patients was the stated survival proportion calculated?
Was it based on patients diagnosed many years in the past? If so, how are changes in the diagnosis
and treatment that might have taken place over time expected to change the prediction for patients
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diagnosed today?
Thirdly, the population-based data from which grouped estimates of survival often come, is inher-
ently observational and must always be interpreted in this context. Communicating uncertainty in
predictions and explaining that there is no such thing as being able to predict the exact course of
disease for a speciﬁc individual is a challenging task for any provider and communicator of statistics
targeted to patients or to the general public.
Lastly, even the most carefully calculated and interpreted estimates of survival do not account for
other aspects of treatment and rehabilitation, such as quality of life issues that might be of equal,
or even greater concern to the patients than the actual prospect of surviving ﬁve more years.
The bottom line is that all attempts to communicate medical information involves translating, often
high-level, information into meaningful messages for diﬀerent types of audiences. This requires:
1. a good understanding of what type of information is expected from the counselee.
2. easy-access to systematically structured and up-to-date disease-speciﬁc data.
3. standardized communication materials to avoid misinterpretation resulting from inconsistent
presentation.
4. comprehensive disease-speciﬁc tools that facilitate patient comprehension and that can be
adapted for individual levels of numeracy, literacy and susceptibility to framing eﬀects (i.e.,
how small changes in the format of numerical information may dramatically alter the percep-
tion of the presented information [16]).
Recommendations that meet the above requirements and that aim to optimize risk communication
between doctor and patient are, however, not always straight forward to implement in practice. For
example, while there is a consensus that the main care provider has the greatest insight into the
clinical management of the individual patient, factors that include lack of easy-access to appropriate
data and tools for satisfactorily explaining the data to the patient, limited face-to-face time for
patient consultations, and uncertainty whether the patient actually is ready for, or even wants
to take an active role in her management, adds complexity to risk communication. In addition,
individuals diagnosed with severe illnesses such as cancer have been reported to also seek information
about their disease outside the health care system. In the end of 2011 in Sweden, 89% of all Swedish
households were equipped with a computer that had access to the internet, 71% of all Swedes were
reported to access the internet on a daily basis, and 23% of the users looked for health information
online at least monthly according to a report issued be the World Internet Project [17]. Among
individuals diagnosed with cancer in Sweden, the proportion of patients that use the internet to
access information about their disease has increased markedly in the past 15 years, going from
16% in 1998 to 61% in 2008 [18, 19]. Swedish cancer patients have also been found to pay closer
attention to media reports about cancer than non-cancer patients [18] which puts high demands
not only on health care professionals, but also researchers, medical reporters, support groups and
other providers of health-related information to the public.
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4 Material
4.1 Cancer registration in Sweden
Established in 1958, the Swedish Cancer Register (SCR) is one of the world's oldest cancer registers.
The SCR is maintained by the National Board of Health andWelfare and encompasses all individuals
with an oﬃcial residency in Sweden. Notiﬁcation of all malignant tumours (as well as certain benign
tumours) is statutory according to the Health Data Registers Act [20], and reports of incident
tumours are typically submitted from at least two sources (physicians, pathologists or cytologists)
[21]. National cancer registration in Sweden is based on data collected regionally via six Regional
Cancer Centers (RCC). Each RCC is situated in one out of six health care regions in Sweden, and
the notiﬁcation of new cancer cases are continuously recorded via the RCCs. The RCCs not only
enters the reported tumours into a computerised database, but also perform coding and logical
checks, including investigation of cases that lack complete clinical, histopathological or cytological
reports. In October each year, the data from the previous calendar year is delivered from each RCC
to the National Board of Health and Welfare, and included the SCR. The forwarded data consist
primarily of information on diagnoses codes, histological subtype, stage (available since 2004), means
of detection, and where the cancer was diagnosed.
In addition to preparing and delivering regional cancer data to the National Board of Health and
Welfare, the RCCs also host 28 cancer quality registers. The quality registers are decentralised
health registers that are administered via a common IT-platform, INCA (Information Network for
Cancer Care), which is maintained jointly be the RCCs. Each quality register has been initiated
by physicians and other health care professionals, and is used for monitoring the quality of the
care and management of cancer patients in Sweden. The scope of information related to patient
(host), tumour and treatment that is reported to, and recorded in, the quality registers is more
detailed than that of the national SCR. As such, the quality registers are often used in register-
based epidemiological studies, as well as a starting point for clinical research. A summary of the
data ﬂow and organisational structure of Swedish cancer registration is summarised in Figure 1.
4.2 Data material used in this thesis
4.2.1 Cancer data
In this thesis, data from the SCR was used in studies II (breast cancer), III (Hodgkin lymphoma)
and IV (melanoma, colon cancer and acute myeloid leukemia). For study I, data from the National
Prostate Cancer Register (NPCR) was used. The NPCR is a quality register that was established in
the South-East health care region of Sweden in 1987, and which reached national coverage in 1998.
The NPCR records all new cases of prostatic adenocarcinoma and is regularly updated against
the SCR. In terms of completeness, the NPCR encompasses more than 96% of all prostate cancer
reported to the SCR [22]. In addition to basic demographic data of the patient, the NPCR also
contain detailed clinical data, such as, stage according to the TNM-classiﬁcation system, tumour
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Figure 1  Organisational structure of cancer registration in Sweden
grade according to the Gleason grading system, serum Prostate Speciﬁc Antigen (PSA) level at the
time of diagnosis, as well as intended treatment.
4.2.2 Death data
Both the SCR and the NPCR are regularly linked to the Swedish Cause of Death Register (CDR)
to retrieve information on dates of death (if applicable) that enable patient follow-up. The CDR
was initiated in 1961 and includes all deceased individuals who were residents in Sweden at the time
of their death. Stillborn children, temporary residents, and Swedes who had oﬃcially emigrated
from Sweden at the time they died are not included in the register. However, this is usually not a
problem in cancer patient survival studies since the Swedish Cancer Registry have merged the SCR
to data that contains information about all recorded emigrations from Sweden. The emigration
dates are used in our analyses to censor individuals who emigrate during follow-up.
The CDR also includes information about the underlying and contributing causes of death, classiﬁed
according to the version of the International Classiﬁcation of Diseases (ICD) in force at the time.
All studies in this thesis used dates of death linked from the CDR. In addition, Study II and III
used explicit information about the underlying cause of death of deceased individuals in order to
identify patients whose death was attributable to diseases of the circulatory system.
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4.2.3 Population Statistics
Sweden has an over 300 year long history of keeping and continually updating a population register
containing information about the actual number of people living in the country. Initially, registration
was made possible via church records in each parish, but from 1749 population statistics were
systematically collected and summarized by Tabellverket. However, it was not until after a major
re-organisation of the compilation of population statistics in 1858, when Statistics Sweden was
founded, that the quality of the statistics became satisfactory. As of 1860, the data on population
and death counts is thought to have been nearly 100% complete [23]. Since then, Statistics Sweden
has remained the administrative agency responsible for producing and publishing oﬃcial Swedish
statistics for public information, planning and research purposes. Today, the population statistics
are compiled using data from population records at the Swedish Tax Agency.
In this thesis, population life tables, stratiﬁed on age, sex and calendar year, were used in all four
studies. The life tables were, nevertheless, not obtained directly from Statistics Sweden but from
the Human Mortality Databases (HMD) project. The HMD is a collaborative project that was
launched in 2002 in order to provide open, international access to detailed mortality and population
data to researchers, journalists, policy analysts among others. It is a joint project that primarily
involves research teams in the Department of Demography at the University of California, Berkeley,
USA, and at the Max Planck Institute for Demographic Research, Germany. The Swedish raw data
is submitted to the HMD by Statistics Sweden and adjusted and processed according to a common
methods protocol prior to being converted to the life-tables that are available for public use [24].
4.3 A note on record linkage
Data from the population and health registers were linked using the Swedish personal identity
number that is assigned to every person who is born in Sweden, as well as immigrants who intend
to stay in Sweden for at least one year. The personal identity number was ﬁrst introduced in
Sweden in 1947, and has since become a vital component of Swedish health care administration by
enabling tracing of patients and their medical records, and register linkages for research purposes
[25]. The personal identity number consists of three parts; the date of birth, a three-digit birth
number and a check digit and makes it possible to trace virtually any patient through, not only
the national health registers, but also other registers that contain population-statistics, such as
migration, education, taxation, and income statistics. Medical research projects that require record
linkage must be reviewed and granted by an Ethics review-board, and in practice, the linkage is
done at the National Board of Health and Welfare or Statistics Sweden where the personal identity
number is replaced by a serial number in order to make the individual records anonymized before
the data is released to researchers.
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5 Statistical methods
5.1 Relative survival and excess mortality
All statistical methods used in this thesis build upon the theory of relative survival. The concept of
relative survival was introduced for the ﬁrst time in 1942 [26] and has since then become the method
of choice for estimating population-based cancer patient survival [11]. Relative survival provides a
measure of excess mortality associated with cancer, i.e., the mortality rate above and beyond what
is expected in a comparable group of individuals free from the cancer in question. It is calculated
without using explicit cause of death information, by contrasting the all-cause survival experienced
by the patients, to the expected survival in a comparable group of individuals, free from the cancer
in question. Formally relative survival, R(t) at time t after diagnosis can be written as
R(t) =
S(t)
S∗(t)
, (1)
where S(t) is the all-cause survival among the patients and S∗(t) is the expected (all-cause) survival
in the comparison group, free from the studied cancer. The excess mortality, denoted by λ(t) at
time t is
λ(t) = h(t)− h∗(t), (2)
where h(t) is the all-cause mortality rate experienced by the patients and h∗(t) the corresponding
expected mortality rate. The expected survival (and mortality) is typically obtained from the
National Bureau of statistics and stratiﬁed on characteristics such as sex, age and calendar year.
Relative survival aims to provide an estimate of net survival. Net survival is interpreted as the
survival experience of the patients in the absence of competing causes of death. For example, a
ﬁve-year net survival of 0.8 provides an estimate of the proportion of patients who would survive
at least 5 years after their diagnosis of cancer, 80% in this example, if it was possible to remove all
causes of death except the cancer in question. Although there is occasionally a mistake belief that
relative survival and net survival represent the same quantity, the interpretation of relative survival
as net survival is only valid under the following assumptions,
1. The time to death from the cancer in question is conditionally independent of the time to
death from other causes. By conditional independence we mean that there are no factors
that inﬂuence both cancer and non-cancer mortality other than those factors that have been
controlled for in the estimation via stratiﬁcation or regression modelling. This is commonly
referred to as the independence assumption.
2. The cancer patients are exchangeable to the comparison population that gave rise to the ex-
pected mortality rates (typically conditional demographic covariates like age, sex and calendar
year).
3. An appropriate estimator is used.
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Due to the fact that the cancer and non-cancer mortality typically share the inﬂuence of the same
demographic covariates, it has been shown that the most commonly used estimators for calculating
a single summary measure of the life-table estimates of relative survival do, in fact, yield biased
estimates of net survival [27]. The reason for this is that a single (averaged) expected mortality rate
is applied to a group of heterogeneous individuals. However, adjusting the relative survival estimates
for age, e.g., by stratiﬁcation or standardisation, reduces the bias in all classical estimators [28]. The
recently proposed Pohar-Perme method, on the other hand, yields unbiased estimates of net survival
for a group of cancer patients as a whole, in a setting that does not require stratiﬁcation or regression
modelling. The Pohar-Perme method is therefor anticipated to become the preferred method for
reporting cancer patient survival statistics in the future in situations where one single summary
measure of cancer patient survival is of interest, e.g., in cancer registry reports [29, 30, 31].
In this thesis we will use multivariable regression to model relative survival (excess mortality).
Individual-level modelling of the excess mortality removes, to a certain extent, the problem raised
above since it appropriately incorporates the demographic covariates in question in the estimation
[27, 28]. However, any regression model is dependent upon the validity of all additional assumptions
that are made in the model. For example, if there are additional covariates not included in the model
that share inﬂuence on cancer and non-cancer mortality, the model-based relative survival estimates
will not be estimates of net survival.
5.1.1 Modelling excess mortality using ﬂexible parametric survival models
In survival analysis, regression models are usually ﬁtted on the (log) mortality scale, as opposed to
the survival scale. This is also the case in relative survival analysis, and a range of regression models
for excess mortality have been proposed. To date, models where the baseline excess hazard function
is assumed to take a parametric form, and where covariates are assumed to act multiplicatively
on the excess hazard, have been used most commonly in applied research [32, 33, 34, 35, 36, 37].
Non-parametric [38, 39] and fully additive regression models [40, 41, 42] have also been developed to
model excess mortality but have been used less often in practise in population-based cancer patient
survival analysis.
In this thesis, ﬂexible parametric survival models were used. Flexible parametric models are
ﬁtted on the log cumulative excess hazard (mortality) scale and use restricted cubic spline functions
to explicitly model the (log cumulative) baseline excess mortality function [37]. That is, on the
cumulative hazard scale the all-cause cumulative mortality, H(t), at time t is
H(t) = H∗(t) + Λ(t), (3)
where H∗(t) is the cumulative expected all-cause mortality in the general population (matched on
sex, age and calendar year), and Λ(t) is the cumulative excess mortality. The ﬂexible parametric
survival model assumes that H∗(t) is a known quantity and that Λ(t) is the random component
subject to regression modelling. By assuming that the cumulative excess hazard is a multiplicative
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function of the covariates, x, and that the eﬀects are proportional with respect to the underlying
time scale, a model for Λ(t) can be written as
ln(Λ(t;x)) = s(ln(t);γ0) + x
Tβ. (4)
Here Λ(t) is represented by restricted cubic splines for ln(t), s(ln(t);γ0), characterised by the vector
of parameters associated with the basis functions for the spline, γ0, and the eﬀects of covariates, x,
which are given by β. The restricted cubic spline function, s(ln(t);γ0), is deﬁned as,
s(ln(t);γ0) = γ00 + γ01v1(x) + γ02v2(x) + ...+ γ0K−1vK−1(x), (5)
where K is the number of knots and the jth basis function is deﬁned as,
vj(x) =
x, if j = 1(x− kj)3+ − λj(x− kmin)3+ − (1− λj)(x− kmax)3+, if j = 2, ...,K − 1. (6)
Under this deﬁnition, u+ = u if u > 0 and u+ = 0 if u ≤ 0, kmin is the position of the ﬁrst knot,
kmax the position of the last knot, and λj =
kmax−kj
kmax−kmin .
The proportional excess hazards model in (4) can easily be extended to handle time-dependent
covariate eﬀects by including interaction terms between the time-dependent covariates and a new
set of restricted cubic spline terms. Modelling of time-dependent eﬀects generally require fewer
knots than the baseline eﬀects [37] so for each time-dependent eﬀect, xi, a new conﬁguration of the
knots may be chosen. This gives,
ln(Λ(t;x)) = s(ln(t);γ0) + x
Tβ +
D∑
i=1
s(ln(t);γi)xi (7)
where D is the number of time-dependent covariate eﬀects and s(ln(t);γi) is the spline function for
the ith time-dependent eﬀect. Note that for each of the D time-dependent eﬀects represented by xi
in the model above are typically a subset of x.
The model parameters are estimated by maximising the log likelihood function derived by Nelson
et al [37]. The likelihood contribution for each subject is
lnLi = di ln
[
h∗(ti) +
1
ti
d
dxi
(s(xi;γ0)) exp(ηi)
]
− exp(ηi)
where xi = ln(ti), and ηi is the linear predictor corresponding to individual i in the ﬂexible para-
metric model as expressed in (4). The extension to left truncated data can easily be made by adding
the term exp(η0,i) to the above likelihood contribution for each subject. In this setting, exp(η0,i)
corresponds to individual i's linear predictor at her entry time, t0,i. That is,
exp(η0,i) = s(ln(t0,i);γ0) + x
Tβ.
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The maximisation of the log likelihood function, lnL =
∑n
i lnLi was done using the Newton-
Raphson algorithm [43].
5.2 Period analysis
A potential problem with survival estimates based on patients diagnosed ﬁve or ten years back
in time is that they might no longer be valid for newly diagnosed patients. The introduction
of new eﬀective treatments could, for example, alter the conditions and prospect for recovery and
rehabilitation for the patients who receive it, compared to those who previously did not. The survival
estimates calculated from the patients who were diagnosed and treated prior to the introduction
of the more eﬀective treatment would paint an overly pessimistic picture of the future for patients
diagnosed in more recent years. As a means to predict cancer patient survival in a manner that
improves the timeliness of survival, estimates period analysis was introduced for cancer patient
survival by Brenner and Gefeller about 15 years ago [44].
The conceptual idea behind period analysis is illustrated here using a mock sample of 4 cancer
patients diagnosed between 1996 and 2003 and followed for death or censoring until the end of
2005. In Figure 2 solid lines have been drawn to represent the length of follow-up of each of the
four patients. In a classical complete cohort analysis, subject 1 would enter the cohort at the date
of her diagnosis in 2003, and be followed through time until the date of death or censoring (due
to loss from follow-up or administrative censoring which occurred in 2005). Thus, subject 1 would
contribute to the riskset in calculations of survival up to 2 years after her diagnosis. Similarly,
subject 2 would contribute to the riskset up to 4 years after the diagnosis etc. In a period analysis,
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Figure 2  Cohort of 4 cancer patients and their contribution to a survival analysis
only a subset of each subjects follow-up is incorporated into the survival calculations. Which part
is included depends on when the patient was diagnosed with cancer, and on the period window.
Since period analysis aims to improve the timeliness of survival estimates, a period window that
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includes only the most recent years for which data are available is typically chosen. In Figure 3,
the years 2002 through 2005 deﬁne the period of interest, and only follow-up within this window
is incorporated in the survival calculations. For subject 1, this corresponds to the full follow-up,
i.e., the same amount of information is included in the period analysis as in a complete cohort
analysis. For subject 2 the survival time between the date of diagnosis and year 2002 is ignored,
and subject 2's contribution to the riskset is thereby restricted to the survival calculation beyond
the 2 ﬁrst years after the diagnosis. Subject 4, who exited the study prior to the period of interest
is entirely left out from the analysis. Thus, only the most recent data are used for estimation of
short-term survival, i.e., the time during patient follow-up when temporal improvements in cancer
patient survival are typically observed [45]. The timeliness achieved by using only recent data for
estimation of short-term survival also carries over to estimates of long-term survival, even though
historical data is required to estimate of the latter.
In practice, period estimates are obtained by left-truncating all observations at the beginning of the
period window and by right censoring them the end [44]. As such, period estimates do not come
from a well-deﬁned cohort of patients but from a synthetic cohort with varying degree of inclusion
in the analysis. Empirical evaluations of period analysis have demonstrated a very good agreement
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Figure 3  Synthetic cohort based on 4 cancer patients and their contribution to a period survival
analysis
between survival estimates projected using the Brenner approach and what actually happened to the
patients once suﬃcient follow-up was available to calculate traditional cohort estimated of survival
[46, 47, 48]. A period approach to estimation was applied in study I of this thesis.
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5.3 Statistical methods for competing risks
Under the independence assumption, relative survival aims to estimate net survival1, i.e., survival
in the hypothetical situation were deaths from other causes have been removed. Statistical methods
for competing risks, on the other hand, are used to calculate so called crude survival probabilities2.
These are interpreted as cancer-speciﬁc survival probabilities in the situation where other causes of
death also exist. From a risk counselling perspective, estimates of net survival may not appropriately
describe the most likely course of the disease since they, by deﬁnition, will underestimate the actual
cancer-speciﬁc survival. The distinction between net and crude survival is illustrated in Figure 4
using data from the Swedish NPCR to summarise prostate cancer survival within the ﬁrst 10 years
after diagnosis, among men diagnosed between 2005 and 2009. First we note that the complement of
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Figure 4  Net and crude probabilities of death in Swedish men diagnosed with prostate cancer between
2005 and 2009.
the net and crude survival is drawn (i.e., one minus the survival probability), as is tradition in most
competing risks applications. The shaded areas in the graphs on the left-hand side represent the
net probabilities of prostate cancer death as a function of years since diagnosis. For a 75-year-old
man diagnosed with prostate cancer, the probability of dying of prostate cancer within 10 years is
0.27 in a world where it is not possible to die of other causes. When acknowledging the existence of
competing causes of death, we see that the crude probability that such a man will die of prostate
cancer during the same time interval is only 0.18 (top right hand graph). In the same panel we
also see that the probability of dying of a cause other than prostate cancer within 10 years is 0.43,
and the probability of still being alive after 10 years is 0.39. The diﬀerence between crude and net
probabilities is not as great for the 60-year-old men since the probability of death due to causes other
1Net survival is sometimes referred to as marginal survival [49] or partial crude survival [50] in the competing
risks literature.
2Also referred to as cause-speciﬁc cumulative incidence [49] or absolute survival [51].
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than cancer is not as high. However, the two constructs are conceptually diﬀerent and the choice
between net and crude estimates of cancer patient survival depends on the the research question
that is to be investigated. In the discussion section of this thesis I will outline some general rules
of thumb that may be applied to assess which of the two measures of survival is most appropriate
for a given research question, and what quantities can be estimated from the available data.
On a more theoretical note, the crude probability of dying from cancer, denoted Crc(t), is commonly
expressed by the cause-speciﬁc cumulative distribution function, deﬁned to be Fc(t) = P (T ≤ t, δ =
c), where δ is an indicator that tells that death from cancer, c, is the event of interest [50]. Fc(t)
can be calculated from the cause-speciﬁc hazard rates, hc(t), and the all-cause survival, S(t), via,
Fc(t) = Crc(t) =
∫ t
0
S(u)hc(u)du, (8)
where
S(t) = P (T > t) = exp
{
−
∫ t
0
h(u)du
}
(9)
and
h(t) = lim
∆t→0
P (t ≤ T < t+ ∆t | T ≥ t)
∆t
. (10)
The instantaneous rate at which death due to cause c occurs, hc(t), is deﬁned to be:
hc(t) = lim
∆t→0
P (t ≤ T < t+ ∆t, δ = c | T ≥ t)
∆t
. (11)
In a relative survival setting, estimates of the all-cause survival, S(t) and cancer-speciﬁc haz-
ard, hc(t), are replaced by their relative survival counterparts. This involves replacing S(t) with
S∗(t)R(t) and hc(t) with λ(t), respectively [52]. Hence, the crude probability of death from the
cancer in question can now be re-expressed as
Crc(t) =
∫ t
0
S∗(u)R(u)λ(u)du. (12)
Similarly, the crude probability of death due to causes other than cancer, Cro(t), is given by
Cro(t) =
∫ t
0
S∗(u)R(u)h∗(u)du. (13)
5.3.1 Numerical integration and variance approximation
Expressions (12) and (13) were approximated numerically using the 'brute force' method proposed
earlier by Carstensen [53]. The time scale (time since diagnosis) was split into 1000 intervals of
equal length, and the predicted, interval-speciﬁc values of the integrand, fˆ(tj | x) = S∗(tj | x)Rˆ(tj |
x)λˆ(tj | x) were calculated. The crude probabilities of death were then obtained by summing the
interval-speciﬁc integrands over the 1000 intervals as follows,
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
, (14)
where l is the interval length, i.e., 101000 . fˆ(tj | x) is a non-linear function of regression model
parameters and its variance-covariance matrix was obtained using the delta method. In the setting
of this study, the variance-covariance matrix of the vector fˆ(t | x) is,
Var(fˆ(t | x)) = GVˆ G′, (15)
where G is a matrix of observation-speciﬁc derivatives for each parameter in the model, and Vˆ is
the estimated variance matrix for the model parameters. Similarly, it follows that the variance-
covariance matrix of the vector Cˆrc(t) is,
Var(Cˆrc(t)) = LGVˆ G
′L′. (16)
G were approximated numerically using the Stata command predictnl [43].
This approach to estimate crude probabilities of death from cancer was the main focus of study
I. In study II and III competing risks theory was combined with a novel approach for partition-
ing excess mortality into component parts, and in study IV competing risks theory was used in
combination with a recently developed method for estimating and modelling statistical cure in a
population-based setting [54].
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5.4 Cure
Cure is a summary measure used for quantifying improvements in cancer care and prognosis. Whilst
there does not exist one single unambiguous deﬁnition of cure in the context of cancer patient sur-
vival, three broad deﬁnitions of conceptually diﬀerent constructs have emerged from the ﬁeld of
clinical oncology [55].
• Clinical cure or medical cure refers to the situation where the treatment has eradicated all
signs and symptoms of a patient's disease, and where the cancer in question will not return.
Even in situations when clinical cure is the goal of the treatment, it is intrinsically hard
to objectively measure if an individual patient has reached this goal. In terms of the clinical
management of the patient, there is little practical beneﬁt from being able to separate clinically
cured patients from asymptomatic long-term survivors who live their lives with no evidence
of disease. To quote Robert J. Mayer, MD, a senior cancer researcher at Dana-Farber and
physician at Dana-Farber/Brigham and Women's Cancer Center, "Cure is a word that I don't
use a great deal; it is promising something that may or may not be possible. Instead I say to
patients, You will be alive and well, and in 20 years we'll look back at this and have a chuckle."
[56]
• In a relative survival framework, Statistical cure occurs from the point in time (after diagnosis)
when cancer patients die at the same rate as a comparable group of individuals, free from
the cancer in question. In contrast to clinical cure, statistical cure is deﬁned on a group level
and is relatively straight forward to estimate. As such, the ﬁrst cure model was introduced
by Boag in 1949 [57]. Informally, statistical cure can be estimated by deﬁning an asymptote
to a net survival curve. Figure 5 demonstrates this idea and illustrates how male patients
diagnosed with colon cancer can be partitioned into a statistically cured group and a group
bound to die from their cancer. Because the cured proportion is identiﬁed in a net survival
framework, the interpretation of this measure is limited to the hypothetical situation where
competing causes of death are assumed not to exist.
• Personal cure is a quantity that is not reported often in practise, but which corresponds to
the proportion of cancer patients who are likely to die from a cause other than their cancer.
The terminology is somewhat misguiding since personal cure is, in fact, also deﬁned on a
group level. Moreover, personally cured patients do not necessarily die free from signs and
symptoms of their cancer. In contrast, the patients may die with their cancer. Terminology
apart, this measure is of potential interest to cancer patients who want to understand the
likely course of their disease since its estimation requires consideration of competing risks.
Figure 6 use the same cohort of male patients as in Figure 5 to illustrate the various groups
into which patients may be classiﬁed after they are diagnosed with cancer. At the time of
diagnosis all patients are assumed to be alive. As time progresses some patients will die and,
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Figure 5  Conceptual illustration of statistical cure in 75-year old Swedish males diagnosed with colon
cancer in 2005
at a given point in time during follow-up, the probability that the deaths that have occurred
were caused by the diagnosed cancer versus other causes can be calculated. The proportion of
personally cured patients is obtained by estimating an asymptote to the crude survival curve.
It will, by deﬁnition, be lower than the proportion of statistically cured patients.
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Figure 6  Conceptual illustration of personal cure in 75-year old Swedish males diagnosed with colon
cancer in 2005
5.4.1 Modelling statistical cure
Several models for estimating statistical cure using population-based data have been proposed by,
for example, De Angelis [58], Verdecchia [59], Yu [60], Lambert [61] and Andersson [54]. Apart from
providing an estimate of the proportion of statistically cured patients, cure models also estimate the
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survival function of those that are uncured. Cure models can generally be divided into two classes
of models, mixture models and non-mixture models.
In mixture models, the all-cause survival function, S(t) can be written as,
S(t) = S∗(t)(pi + (1− pi)Su(t)), (17)
where pi is the proportion of patients that will be statistically cured and Su(t) is the cancer-speciﬁc
survival function for the uncured patients [59]. Thus, mixture models build upon the idea that
patients belong to either a cured group (for which the survival function is assumed to equal that
of a comparable disease-free population), or to an uncured group (whose overall survival function
can be described by S∗(t)Su(t)). Mixture models primarily diﬀer with respect to the parametric
distribution that is used to appropriately model, and capture the shape of the cancer-speciﬁc survival
function for the uncured group.
In non-mixture models, the all-cause survival function is instead written as,
S(t) = S∗(t)piFz(t). (18)
Again, pi denotes the cure proportion, whereas Fz(t) denotes some cumulative distribution function,
implying that Fz(t) = 1 − SZ(t), where SZ(t) is a survival function [61]. Fz(t) can be estimated
parametrically, and in practice, the Weibull distribution is often used for this purpose. In contrast
to mixture cure models, the original non-mixture models have a biological motivation that stem
from what is known about tumor growth [62]. The idea is that treated cancer patients may be
left with cancer cells that are capable of forming a new tumour mass, and thereby lead to relapse.
Cured patients are assumed to have no such cells left after treatment, whereas for uncured patients,
FZ(t) represents the distribution function that characterises the time it takes for cancer cells with
proliferate potential to develop into a detectable cancer. This biological motivation for non-mixture
cure models is, however, not relevant in a relative survival setting but the mathematical results
can still be applied to estimate an asymptote representative of the cured proportion (as long as
statistical cure is believed to be a reasonable assumption).
Equation (18) can, nevertheless, be rewritten as,
S(t) = S∗(t)
(
pi + (1− pi)
(
piFZ(t) − pi
1− pi
))
. (19)
Under this form, the survival function of the non-mixture cure model takes the form of a mixture
cure model. Using equation (19) it becomes clear that the survival function of the uncured patients
can be obtained via pi
FZ (t)−pi
1−pi , which is a simply a transformation of the model parameters, in a
non-mixture cure model.
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5.4.2 Flexible parametric cure models
In study IV of this thesis we use ﬂexible parametric cure models to estimate statistical cure. We
subsequently apply competing risks theory to get estimates of "personal cure". Flexible parametric
cure models belong to the family of non-mixture cure models. They are also a special case of the
ﬂexible parametric survival model, outlined previously in equations (4-6). In contrast to other non-
mixture cure models that have been adapted for relative survival, the use of ﬂexible parametric cure
models obviates the need to make strong distributional assumptions about the functional form of the
survival function of the uncured patients and thus oﬀer greater modelling ﬂexibility [54]. It has also
been shown empirically that the ﬂexible parametric cure model tends to perform better than other
commonly used cure models under scenarios where the survival of the patients is either relatively
good (e.g., patients with localized melanoma) or poor (e.g., among elderly patients diagnosed with
AML) [63]. These are situations where most cure models (adapted for relative survival) often fail to
converge, or otherwise provide a poor ﬁt to the data as compared graphically to empirical estimates
of relative survival.
By deﬁnition, statistical cure occurs when the excess mortality, observed in the cancer patients,
reaches zero. Such a scenario can be built into the ﬂexible parametric survival model by constraining
the log cumulative excess hazard function to have zero slope from a certain point in time after
diagnosis. In practice, such constraint is imposed by treating the spline basis functions, vj(x), used
to model the log cumulative excess hazard function in (4) in reverse order, and by restricting the
parameter for the linear spline term to be zero. Thus, for j = 1, ...,K − 1, vj(x) are now:
vj(x) =
x, if j = 1(kK−j+1 − x)3+ − λj(kmax − x)3+ − (1− λj)(kmin − x)3+, if j = 2, ...,K − 1. (20)
where x = ln(t) and λj =
kK−j+1−kmin
kmax−kmin . The parameter for the linear spline variable, γ01, is then
restricted to be 0.
The ﬂexible parametric cure model provides an estimate of the relative survival, R(t), via
R(t) = piFZ(t), (21)
where the cure proportion, pi = exp(− exp(γ00)), and the distribution function, FZ(t) = exp(γ02v2(x)+
...+ γ0K−1vK−1(x)).
When adding a set of covariates, z, and D time dependent eﬀects to the model, R(t) becomes:
R(t; z) = exp(− exp(γ00 + βTz)exp(γ02v2(x) + ...+ γ0K−1vK−1(x)) +
D∑
i=1
s(ln(t);γi) (22)
From (22) it follows that γ00 and β contribute to the modelling of the cure proportion, whereas
parameters that depend on time are used to model FZ(t).
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Flexible parametric cure models have been incorporated into the stpm2 command in Stata [64].
This implementation was used in Study IV.
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6 Study 1: Making cancer patient survival statistics more useful
for patients and clinicians
6.1 Motivation
In the clinical research community there has been, and still is, much confusion about statistical
methods for estimating survival in the presence of competing risks. As a result, a large number of
papers have been published with the aim of clarifying when competing risks methods are needed,
approaches to estimation, assumptions and interpretation of the estimated quantities, see for exam-
ple [49, 65, 66, 67, 68, 69, 70, 71]. In this paper, a general aim was to clarify and discuss the relative
merits of crude and net cancer patient survival in a population-based setting. In addition, we set
out to demonstrate how period analysis, applied in a competing risk setting, can be used to predict
'absolute', (i.e. crude) survival probabilities applicable to newly diagnosed cancer patients. As a
motivating clinical example, we assessed the impact of prognostic factors on the risk of prostate
cancer death in relation to death from other causes than prostate cancer, and event-free survival,
among recently diagnosed patients.
6.2 Data
The target group for the clinical application were all (recently diagnosed) men with intermediate
or high risk localised prostate cancer in Sweden who are candidates for conservative or hormonal
management. The study population was identiﬁed from the cohort of all (n=99,051) men with a
recorded diagnosis of prostate cancer in the Swedish NPCR between 1996-2008. Included in the
study were men with complete stage and treatment information (n = 93,685). Risk groups were
formed according to a modiﬁed version of the National Comprehensive Cancer Network R© classi-
ﬁcation, by combining the recorded TNM stage, tumour grade (according to the Gleason grading
system), and serum Prostate Speciﬁc Antigen (PSA) level at the time of diagnosis. The interme-
diate risk category was deﬁned as clinical local stage T1-2, N0, NX-, M0, MX and serum levels of
PSA between 10-20 ng/ml or Gleason score 7, and the locally advanced high risk category as T3-4,
N0, NX, M0, MX and/or PSA between 20-50 ng/ml and/or Gleason score 8 or higher. Patients not
included in these risk group classiﬁcations, and patients who received curatively intended treatment
were excluded, leaving 29,647 patients in the study population that formed the basis for the syn-
thetic cohort for the period analysis. Figure 7 illustrates the entry criteria to the synthetic cohort.
Under the chosen period window (2005-2009) no patients who died before 1 Jan 2005, (n = 6,294)
contributed to the study-base. Thus, from the study population, 23,353 men were included in the
analysis.
6.3 Methods
Our interest in this study was to estimate crude survival from prostate cancer (target event), versus
crude survival from any other cause, by prognostic factors. A graphical representation of the com-
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Figure 7  Entry criteria to the synthetic cohort used in Study 1
peting risk model used in Study I is provided in Figure 8. We estimated the event-speciﬁc hazard
function that corresponds to the excess hazard due to prostate cancer, λ(t) using a ﬂexible paramet-
ric survival model (with delayed entry), and obtained the expected hazard function in the absence
of prostate cancer, h∗(t) from population life tables. Crude probabilities of death were calculated by
Alive
Dead other
Dead prostate cancer



*
HHHHHHHj
λ(t)
h∗(t)
Figure 8  Competing risk model used in study I
evaluating the integrals in equations (12) and (13) for t ∈ [0, 10]. The integrands were obtained us-
ing the predicted excess hazard, ˆλ(t), and relative survival, ˆR(t) from the ﬂexible parametric model
and by assuming that S∗(t) and h∗(t) were known (given sex, age and calender year). To make
the estimates of relative survival and excess mortality applicable to recently diagnosed patients we
assumed that a period approach to modelling would give timely estimates of relative survival and
excess mortality, and that the expected population mortality rates would remain constant 10-years
into the future. At the time the study was carried out, the latest observed mortality rates available
from the HMD were from 2009.
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6.3.1 Approach to modelling
Table 1 contains a summary of all ﬂexible parametric survival models that were ﬁtted and contrasted
in this study. In all models, 5 df were used to model the baseline excess hazard function. Likelihood
ratio tests (LR-test) were used to formally test the signiﬁcance of additional parameters (e.g.,
for time-dependent eﬀects or interactions) to a given model. When modelling interaction eﬀects
between a covariate modelled using a restricted cubic spline (RCS) and a binary covariate, only the
ﬁrst spline term (i.e., the linear component) was included in the interaction. Model 8 was the ﬁnal
model and used to generate all results in Study I.
Model Covariates included Functional form Df time-dependent eﬀect P-value from LR-test
1 Age at diagnosis RCS 5 df N/A -
2 Age at diagnosis RCS 5 df 3 < 0.001
3 Same as model 2 +
Treatment binary N/A < 0.001
4 Same as model 3 +
Risk category binary N/A < 0.001
5 Same as model 4 +
Risk category binary 3 0.0128
6 Same as model 5 +
Treatment binary 3 < 0.001
7a Same as model 6 +
Age x Risk category RCS 1 df N/A 0.5037
7b Same as model 6 +
Age x Treatment RCS 1 df N/A 0.0025
8 Age at diagnosis + RCS 5 df 3
Treatment + binary 3
Risk category + binary 3
Age x Treatment + RCS 1 df N/A
Risk category x Treatment RCS 1 df N/A 0.031
Table 1  Summary of approach to modelling excess mortality
6.4 Findings and discussion
The idea behind this paper was to demonstrate how the combined use of competing risks theory, and
statistical methods suitable to predict survival of newly diagnosed cancer patients, can provide data
that can form a basis for risk counselling. Although such statistics are sought after by some patients
and physicians, a responsible use of the information makes great demands on both its producers and
consumers. At best, a carefully conducted statistical analysis of population-based data can provide
a reasonable guess of survival estimates of newly diagnosed patients. At worst, it can mislead and
give false hope to patients and their families. In this study, we provided a general discussion of the
interpretation and assumptions of commonly reported statistics of population-based cancer patient
survival. An overall aim was to raise the level of understanding for such statistics, and the discussion
was centered around the following issues:
• Net and crude survival are conceptually diﬀerent constructs that both have a place in cancer
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care programmes, although the latter is more useful in the communication of risk between
clinician and patient.
• A prediction model is only as good as the information that goes into it. In principle, individual-
level prediction is the goal. In practice, the data available for modelling in population-based
health registers are limited, and results must typically be interpreted on a group level.
• The manner in which survival statistics are presented to patients and their families, and the
tools that are used for the purpose of conveying complex information, are instrumental in risk
counselling.
• Careful consideration of the limitations that arise from statistical assumptions must be made
when interpreting the results of any statistical analysis. In the setting of this study, these
include assumptions made in relative survival versus cause-speciﬁc survival, sensitivity to
modelling assumptions (inclusion of relevant prognostic factors, consideration of interaction
eﬀects, functional form of covariates, departures from the proportional hazard assumption,
and the chosen approach to project the prognosis of patients).
The above points were highlighted in the context of prostate cancer patient survival in Sweden.
In recent years, scientiﬁc papers that report estimates of crude prostate cancer survival have, in
fact, become quite common [72, 73, 74, 75, 76]. We believe that the results from such reports are
considerably more useful in a clinical setting than estimates of net survival, which do not provide
an ideal basis for risk counselling as they are only interpretable in a hypothetical world (in which
the patients do not live).
One aspect of risk counselling involves providing tools that can help patients make an informed
decision about their preferred medical treatment. The use of observational cancer data for this
aim is, nevertheless, suboptimal and results of the type presented in this paper should not be
used in isolation, but in combination with evidence from randomized clinical treatment trials. For
illustration, in the past 15-20 years there has been a rapid increase in (primarily) low, intermediate,
and high risk localized prostate cancer, where a large contribution follow from the increased use of
the PSA test [77, 78, 79]. Because the uptake of the PSA test, and the diagnostic work-up is skewed
towards men who are healthier than the general population, strong selection mechanisms gave rise
to our cohort [72]. This has consequences for the validity of relative survival analyses which assume
that the patients are exchangeable to the general population (free from prostate cancer). As a means
to circumvent this problem, our study did not include men with low-risk prostate cancer, a group
where estimates of relative survival were > 1 for certain combinations of the covariates. However,
it is possible that men who are at lower risk of dying of all-causes than the population at large are
also, to some extent, overrepresented among men with intermediate and high risk localized prostate
cancer. In addition, the results in this study indicate the presence of another selection mechanism
that relates to how patients are assigned to treatment. When comparing, men in the same risk
group and of the same age, men who receive hormonal therapy have a dismal prognosis compared
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to men who are managed conservatively. This is probably best explained by the fact that men who
are assigned to hormonal treatment at diagnosis are generally in poorer health compared to men
who are eligible for watchful waiting (i.e., deferred hormonal treatment until clinical progression)
and active surveillance (i.e., deferred curative treatment until perceived disease progression). The
strong selection to the cohort and the indication to treatment warrant additional investigation and
consideration of host-factors that predict all-cause survival. This can, for example, be done by
expanding population life tables by indices such as socioeconomic position or level of comorbidities.
Another way to achieve a more appropriate match of patients to the general population is to use
the biological age (as opposed to chronological age) of patients as matching factor in the analysis.
The estimation of biological age involves consideration of comorbidities in the group of patients, but
obviates the need to ascertain the level of comorbid conditions in the entire back-ground population.
If it is believed that the cause of death classiﬁcation of prostate cancer patients is reliable, a third
alternative is to estimate cause-speciﬁc survival, i.e., make explicit use of the recorded cause of
death in the analysis (as opposed to estimate relative survival).
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7 Study 2: Partitioning of excess mortality in population-based
cancer patient survival studies
7.1 Motivation
An attractive feature of relative survival is that it provides an estimate of the excess mortality
associated with a diagnosis of cancer. Excess mortality captures both the direct and the indirect
contribution of cancer to mortality, as opposed to cause-speciﬁc survival which is limited to measure
the direct contribution. Direct causes are all causes of death that would typically be classiﬁed as
death from the cancer in question on the death certiﬁcate and include, for example, malfunctioning
and failure of vital organs where the cancer was originally situated (or metastasized to) and cachexia.
Indirect causes of death include late eﬀects from treatment, e.g., cardiovascular complications,
secondary malignancies, infections (that may be too hard for someone with terminal cancer to
ﬁght), and suicides. Late adverse health eﬀects in cancer patients is a growing problem given
the longer survival seen for most cancers. For example, in breast cancer survivors, several studies
have identiﬁed an increased risk of cardiovascular disorders, mainly myocardial infarction, possibly
associated with radio- and chemotherapy such as anthracyclines [80, 81]. These deaths are not
straight forward to study since:
1. the physician that signs the death certiﬁcate can never know for certain if a cardiac event was
induced by a treatment administered many years in the past or not.
2. indirect deaths are not immediately identiﬁable using a standard relative survival analysis
(which provide an estimate of the overall excess mortality associated with cancer).
In this study we extended ﬂexible parametric survival models for relative survival, with the aim to
partition the overall excess mortality from cancer into two component parts; excess mortality from
diseases of the circulatory system (DCS), and remaining excess cancer mortality.
7.2 Data
The method is illustrated using data on 70,655 women diagnosed with breast cancer in Sweden
between 1973 and 1992 obtained from the Swedish Cancer Register. The restriction to diagnoses
before 1993 ensured that all women had a potential follow-up of at least 15 years. Among these
women, there were 40,361 death in all, of which 8,939 were classiﬁed as any disease of the circulatory
system (according to the information stated on the death certiﬁcate).
The extended model requires population life tables that are stratiﬁed on broad categories of cause
of death. These were constructed using individual-level data containing information about year of
death, age at death, sex, underlying cause of death for all people who died in Sweden between 1961
and 2007. Two sets of life tables were constructed, one corresponding to the expected mortality
rates from DCS, and one corresponding to the expected mortality from causes other than DCS.
Data on population size, N , the total number of deaths, d, in Sweden and the total number of
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DCS deaths, dDCS , for the years 1973-2007 were obtained by year of occurrence from the HMD
and the National Board of Health and Welfare, and were collapsed over sex, age and calendar year.
Probabilities of death due to DCS and non-DCS were estimated by taking the ratio of the death
counts and population at risk in matched intervals of age (i), sex (j), and calendar year (k). The
corresponding mortality rates were then calculated using
h∗DCS,i,j,k = − ln(1−
dDCS,i,j,k
Ni,j,k − dDCS,i,j,k2
) (23)
and
h∗other,i,j,k = − ln(1−
d− dDCS,i,j,k
Ni,j,k − (d−dDCS,i,j,k)2
). (24)
7.3 Methods
In a ﬂexible parametric model (adapted for relative survival), the cumulative hazard at time t can
be written as the sum of the cumulative expected hazard, H∗(t), and the cumulative excess hazard,
Λ(t), according to expression (3). We now instead consider an alternative expression for H(t),
H(t) = H∗DCS(t) +H
∗
Other(t) + ΛDCS(t) + ΛOther(t). (25)
where H∗(t) has been partitioned into the expected mortality from DCS, H∗DCS(t) and other causes
than DCS, H∗Other(t), and Λ(t) into the excess mortality from DCS, ΛDCS(t), and other causes than
DCS, ΛOther(t), respectively. H
∗
DCS(t) and H
∗
Other(t) are assumed to be known from population life
tables, and ΛDCS(t) and ΛOther(t) are estimated from a ﬂexible parametric survival model. Thus,
our interest is now in modelling the time to death from cancer induced DCS, and the time to death
from other (non-DCS) cancer related causes. The corresponding excess hazard rates are depicted
in Figure 9, together with a third outcome of potential interest, death from causes unrelated to the
diagnosed cancer.
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Figure 9  Competing risk model used in study II
Important to remember is that, under this model, expected deaths from DCS are included in the
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box that represents death from other causes than BC. The DCS deaths that occur as a consequence
of treatment only constitute a small proportion of all DCS deaths combined.
In principle, λDCS(t) and λother(t) can be estimated using two separate ﬂexible parametric models,
ln(Λj(t;x)) = s(ln(t);γ0,j) + x
Tβj , j ∈ {cvd, other} (26)
where s(ln(t);γ0,j) provides an estimate of the log cumulative baseline excess mortality for cause j,
and the vector βj represents the covariate eﬀects on cause j. However, an alternative approach to
modelling, that allows for more ﬂexibility in modelling the eﬀects of covariates, is given by,
ln(Λj(t;x)) = s(ln(t);γ0) + x
Tβ + cj(βcvd + s(ln(t);γcvd) + x
Tβcvd) (27)
where
cj =
0, if j = other;1, if j = DCS.
Using this approach, the two outcomes are estimated jointly by including a binary covariate, c, with
cause of death information that enables estimation of separate baseline excess hazard functions for
the diﬀerent outcomes. The covariate eﬀects, xβTj , are assumed to be common for the two causes
of death, but this assumption can be relaxed by including additional interaction terms between a
subset (or all) of the covariates and c. The component-speciﬁc excess mortality rates, λj(t), are
related to Λj(t) via λj(t) =
d
dtΛj(t).
Before a model of type (27) can be ﬁtted, the data set must be transformed into long format. This
is a common way to structure data sets prior to competing risks analyses, and involves assigning
each individual as many observations in the new data set as there are outcomes under investigation.
Moreover, a covariate that indicates cause of death is needed, as well as a death indicator for the
speciﬁc cause. An example is shown below.
+--------------------------------------------------------+
| id entry exit dead cause rate sex agediag |
|--------------------------------------------------------|
| 5464 0 20 0 DCS .00038 2 23 |
| 5464 0 20 0 Other .00120 2 23 |
|--------------------------------------------------------|
| 6851 0 .74590164 0 DCS .00109 2 57 |
| 6851 0 .74590164 1 Other .00427 2 57 |
|---------------------------------------------------------
| 7129 0 7.6939891 1 DCS .00026 2 34 |
| 7129 0 7.6939891 0 Other .00153 2 34 |
|--------------------------------------------------------|
In this sample data set, individual with id = 5464, was followed for 20 years and was still alive
at the end of follow-up. Individual 6851, on the other hand, was followed for 0.75 years after which
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she (sex = 2) died from a cause unrelated to DCS. Similarly, individual 7129 was followed for 7.69
years before she died from some disease of the circulatory system. In this data set, rate denotes the
age-, sex- and calendar matched expected mortality rate from DCS and other causes, respectively.
Models of type (27) estimate the component-speciﬁc3 excess hazard rates. Similar to a 'standard'
competing risk model, as described in equation (12), the component-speciﬁc excess hazard rates can
be used to calculate crude probabilities of death. The extension from (12) to component-speciﬁc
crude probabilities of death is immediate
Crcan,j(t) =
∫ t
0
S∗(u)R(u)λj(u)du, j ∈ {cvd, other} (28)
but requires the additional step of calculating R(u) =
∏
j Rj(u).
7.4 Findings and discussion
In this study we present a number of summary measures for quantifying the risk for death from late
eﬀects of treatment relative to the overall risk of dying of breast cancer, or causes unrelated to the
cancer. Component-speciﬁc excess mortality rates (and rate ratios) were used to assess the impact
of prognostic factors on excess DCS mortality. Without making an assumption about independence
(i.e., between deaths from breast cancer, both DCS and non-DCS, and other causes) these cannot
be interpreted as net mortality rates from excess DCS. Instead, they describe the excess rate at
which women with breast cancer die of DCS, in the real world where other causes of death also
exist. Although estimates of net survival (or net mortality) are the gold standard for epidemiological
studies into the causes and risk of cancer, in practise, the independence assumption is often not
satisﬁed, and inference is then based on the real-world mortality rates. There is, nevertheless,
no one-to-one relationship between the latter and crude survival probabilities. Competing risks
methodology is therefore required to estimate the (real-world) survival probabilities from diﬀerent
causes of death. Figure 10 summarizes temporal trends in the 15-year crude probabilities of death
from diﬀerent causes among women diagnosed with breast cancer at ages 55, 65 and 75 respectively.
Overall the probability of treatment-related DCS is very low (< 0.05) in relation to the probability
of dying from other causes (from breast cancer, or unrelated to breast cancer).
We assume that the excess DCS mortality is associated with the cancer in question and, more
speciﬁcally, that the excess DCS mortality is induced by the treatment. This is not a testable
assumption, but its validity relies primarily on:
1. The quality of the information stated on the death certiﬁcates. Even though the excess DCS
mortality rate is estimated in a relative survival framework, we must broadly categorise all
underlying causes of deaths into either DCS or non-DCS in order to identify the deaths that
occur in excess to what is expected in a comparable group of women free from breast cancer.
3These are sometimes referred to as cause-speciﬁc hazard rates [49] or transition intensities [82] in traditional
competing risk and multistate model literature
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Figure 10  Temporal trends in component-speciﬁc crude probabilities of death among women diag-
nosed with breast cancer in Sweden between the years 1973 and 1992
2. Whether women with breast cancer are exchangeable to the matched general population with
respect to their cardio- and cerebrovascular risk proﬁle, i.e., if the the fact that the women
have breast cancer is the only thing that distinguishes them from the general population with
respect to their risk of developing, and dying from DCS.
Sensitivity analyses, explained in detail in the paper, were carried out and promoted to assess
the impact of miss-classiﬁcations of the underlying causes of death on the estimated excess DCS
mortality rates. In addition, we also estimated excess DCS mortality by laterality. This analysis
was not included in the published paper, but we believe it provides support for the validity of our
approach to estimating excess DCS mortality. It is known that the myocardial exposure of breast
radiotherapy is higher among women treated for breast cancer in the left breast, as compared to
the right breast [83, 84, 85]. Figure 11, shows that this pattern is also present in our data. As
expected, the excess DCS mortality among women treated for breast cancer in their left breast is
higher, and increases with elapsed time since diagnosis. Women treated with breast cancer in their
right breast are also subject to excess DCS mortality (at a lower, and relatively constant, rate).
We speculate that this is indicative of two driving mechanisms for the excess DCS mortality, one
that arise from exposure to radiotherapy (left breast), and another that arise from chemotherapy
related cardiac dysfunction, which become clinically apparent earlier than radiation damages [80].
The excess DCS mortality that is observed in direct relation to the diagnosis is, however, unlikely
to be attributable to treatment, but possibly a severe side-eﬀect from the high levels of psychosocial
stress that is induced by the cancer diagnosis itself [86].
From a public health perspective, being able to study if changes in clinical practise towards
reducing treatment-related mortality have had an impact on patient survival is important. Cardio-
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Figure 11  Timing of excess non-DCS and excess DCS mortality by breast cancer laterality among
women diagnosed in Sweden between the years 1978 and 1982 at ages 70-79.
and cerebrovascular late eﬀects from treatment is merely one indirect cancer consequent death out
of many possible, for example, risk for death from secondary cancers and infections in patients with
Hodgkin lymphoma, or suicide in patients with e.g., lung, prostate, or head and neck cancer. Finer
partitioning of excess cancer mortality would be useful to investigate the relative contribution of
each such cause to the overall risk of dying from the diagnosed cancer. Such analysis would require
additional use of the information stated on the death certiﬁcates and further work should address
under what situations ﬁner stratiﬁcation is feasible.
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8 Study 3: Temporal trends in mortality from diseases of the cir-
culatory system after treatment for Hodgkin lymphoma
8.1 Motivation
Survival after Hodgkin lymphoma has increased substantially in the past four decades and, for
patients aged less than 65 years at diagnosis, the disease is now highly curable [87]. The improved
prognosis is likely attributable to improved patient assessment and staging, the development of
eﬀective multi-agent chemotherapy, introduction of combined-modality therapy with reductions in
radiation ﬁeld size and dose, and more apt evaluation of treatment response. The aim of this study
was to apply the methodology developed in Study II to present clinically interpretable estimates
of temporal trends in the burden of excess mortality from diseases of the circulatory system (DCS)
among Hodgkin lymphoma survivors who were treated in the 1970's through 1990's. In addition,
since the treatments administered to these patients are, to some extent, considered outdated in
modern Hodgkin lymphoma management, we also aimed to predict the future clinical burden among
patients diagnosed and treated in more recent years.
8.2 Data
Included in the study cohort were all patients diagnosed with Hodgkin lymphoma in Sweden between
1973 and 2006 at ages 19 to 79 (n=5,832). These patients were identiﬁed in the Swedish Cancer
Register using ICD7 code 201. No patients were excluded on the basis of previous cancer diagnoses,
although in patients with multiple primary Hodgkin lymphoma diagnoses, we only considered the
ﬁrst diagnosis (n=16 excluded). Patients reported as having suspected, or not microscopically veri-
ﬁed Hodgkin lymphoma were excluded (n = 36). Likewise were patients with a Hodgkin lymphoma
that was diagnosed incidentally at autopsy (n=318), leaving 5,462 patients in the analysed cohort.
The prognostic factors under investigation were sex, age at diagnosis and calendar year of diagnosis.
8.3 Methods
8.3.1 Approach to modelling
We estimated the component-speciﬁc excess DCS mortality rate, and remaining (non-DCS) ex-
cess mortality using ﬂexible parametric survival models of the type described in Study 2. Each
component-speciﬁc baseline excess hazard function was modelled using 5 degrees of freedom (df).
The eﬀects of age and year were modeled continuously and non-linearly using restricted cubic splines,
where the knots were placed at the 5th, 25th, 50th, 75th and 95th percentiles of the distribution
of the two variables, respectively. Moreover, the eﬀects of these covariates were estimated inde-
pendently between the outcomes (i.e., no main eﬀects were assumed to be shared between the two
outcomes) and time-dependently. Time-dependent eﬀects were modeled with 12 df (3 df x 4 param-
eters representing the basis vectors for the age and calendar eﬀects respectively). The assumption
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that the time-dependent eﬀect of calendar year was shared between the outcomes was relaxed by
including a three-way interaction term (between calendar year, cause of death and the time scale).
In all, 57 parameters were estimated in the ﬁnal ﬂexible parametric model. When investigating the
statistical signiﬁcance of interaction terms, we sometimes kept non-signiﬁcant terms in the model
in order to avoid imposing constraints on estimates that were of primary interest. For example, we
did not constrain the eﬀect of calendar year to be the same for both the excess DCS mortality and
the remaining excess mortality since temporal trends in these rates were the main interest of the
study.
8.3.2 Predicting excess mortality and crude probabilities of death into the future
We were only able to fully observe the 20-year excess DCS mortality rate, and remaining excess
mortality rate for patients diagnosed prior to 1988 (due to administrative censoring at 31 Dec 2007).
For patients diagnosed from 1988 and onwards, follow-up was, nevertheless, partially observable,
and used to extrapolate the long-term excess mortality beyond the range of existing data. The
extrapolations were based on the ﬁtted trend (within the observable data) from the model speciﬁed
above. Figure 12 shows how the model-based extrapolation of the 20-year excess DCS mortality
behaves beyond the observable data for patients diagnosed at age 60 and in diﬀerent years. Apart
from any assumptions that were made in terms of specifying a model for the covariate eﬀects, the
extrapolated rates should only be interpreted under the additional assumption that no unpredictable
changes in the general pattern and trends of the mortality of either the HL patients or the general
population occurs.
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Figure 12  Illustration of the estimated excess DCS mortality predicted within the range of observable
follow-up and extrapolated outside the range of follow-up for male patients, aged 60 years at diagnosis,
and diagnosed with Hodgkin lymphoma in Sweden between 1980 and 2000.
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8.4 Findings and discussion
Although excess mortality from DCS is a concern for long-term Hodgkin lymphoma survivors, the
actual risk of dying from such treatment related side-eﬀects is small in relation to the risk of dying
from the underlying disease, or from other causes (unrelated to the disease). The 20-year excess DCS
mortality has decreased continually since the mid 1980's, and is predicted to further decrease among
patients diagnosed in the modern era. There are many possible explanations for these ﬁndings.
The National Care Programme has regularly been updated with regards to principles for treatment,
through restricting to low-dose radiotherapy and reducing and alternating chemotherapy cycles, with
the aim of minimizing the risk for long-term adverse events, without compromising the anti-tumour
eﬀects [88]. However, lack of treatment data in this study, prevented us from disentangling the
relative contribution of these eﬀorts. Other actions to reduce treatment-related cardiotoxicity have
also included patient-speciﬁc recommendations and surveillance visits to estimate the individual
risk proﬁle and enable early detection of symptoms [89].
Few studies on this topic have presented crude probabilities of death as measure of the risk that
Hodgkin lymphoma patients face to die of late cardiotoxic eﬀects from treatment. Moreover, many
authors have recognized the diﬃculty in estimating the eﬀects of long-term treatment complications
in patients diagnosed and treated more recently [90, 91, 92]. This study is novel in the sense that
we have strived to do both these things. Although the panorama of possible late eﬀects attributable
to modern Hodgkin lymphoma treatment are yet to be veriﬁed once the data becomes available, we
argue that, meanwhile, this study maximizes the amount of information that can be obtained from
the available data.
The predicted 20-year crude probabilities of death for patients diagnosed between the years 1988 and
2003 were calculated under the assumption that there will be no changes in the all-cause population
mortality between the years 2007 and 2023. However, the average life span in Sweden has increased
by 2.5 years, on average, per decade since the 1900 [4]. Of all causes that contribute to mortality
in the population, mortality from DCS has decreased most, for both men and women. The relative
reduction in DCS mortality, for individuals aged 30 to 79, over the past three decades has been
approximately 3-4% per year. In order to assess the sensitivity of the published 20-year crude
probabilities of death for patients diagnosed from 1988 and onwards, we also re-did the analysis
using a set of population mortality rates projected for the years 2013-2023 by Statistics Sweden,
using the so called Lee-Carter model [93]. This model incorporates past mortality trends and has
become the leading statistical model for population mortality forecasting, both in the demographic
literature and in practical applications. The Lee-Carter projections are summarised in Figure 13,
whereas Table 2 displays the ﬂat mortality rates that were applied in our study. The projected
mortality rates for individuals up to age 60 are close to those estimated from the Lee-carter model.
However, for individuals older than 60, the rates used in our study are well above the rates projected
by Statistics Sweden.
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Age
Sex 30 40 50 60 70 80
Males 0.7 1.1 3.2 7.1 20.6 66.5
Females 0.3 0.7 2.0 4.8 12.2 44.6
Table 2  Projected mortality rates (per 1000 person-years) used in study III (assumed ﬁxed for the
years 2008-2023)
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Figure 13  Projected mortality rates (per 1000 person-years) for the Swedish population between the
years 2013-2023 using the Lee-Carter model. Source: Statistics Sweden 2013-08-06
The crude probabilities of death from diﬀerent causes that were published in study III are
repeated in Figure 14 (left-hand side). In addition, Figure 14 shows the diﬀerence (expressed in
percentage points) between the published results and the results obtained when population mortality
rates from the Lee-Carter models have been applied instead. The published crude probabilities of
death from other causes than Hodgkin lymphoma are overly pessimistic, as compared to those that
were obtained using the mortality rates projected by Statistics Sweden using the Lee-Carter model.
The diﬀerence between the two approaches was greatest for patients who were 60 years or older at
diagnosis and diagnosed in the most recent years (overestimated by 5 percentage points for patients
diagnosed in 2003). Whilst the direction of these ﬁndings on deaths from other causes than HL are
consistent with what we would expect to observe if the all-cause mortality rates were to decrease in
the future, changing to the Lee-Carter projected mortality rates appears to have a negligible impact
on the crude probabilities of death from Hodgkin lymphoma (DCS or non-DCS).
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Figure 14  Crude probabilities of death (as published), and the diﬀerence (expressed in terms of
percentage points) between the published results and the results obtained when population mortality
rates from the Lee-Carter models have been applied.
We, nevertheless, recommend further investigation into the topic and impact of diﬀerent as-
sumptions for projecting the expected mortality rate in future studies of this kind. A less naive
approach than that applied in the current study might be warranted in other cohorts of patients,
particularly if the interest is in elderly patients.
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9 Study 4: The application of cure models in the presence of com-
peting risks
9.1 Motivation
Estimates of cancer survival in the presence of competing risks are frequently used to relate the
patients' risk of dying from their cancer to that of dying from competing causes, or to still be alive,
as a function of elapsed time since diagnosis. A natural question for patients to ask when faced
with such statistics is related to their chance of being cured from the diagnosed cancer.
In this study we demonstrate how ﬂexible parametric statistical cure models, combined with com-
peting risks theory, can be used to estimate so called 'personal cure' in population-based cancer
patient survival studies.4 We also show how patients who are still alive, and under follow-up, can
be partitioned into two groups as depicted in Figure 15.
Bound to die from cancer
Bound to die from other causes
Alive and not bound to die from cancer
Alive but bound
to die from
cancer
0
.
2
.
4
.
6
.
8
1
Cr
ud
e 
pr
ob
ab
ilit
y 
of
 d
ea
th
 
0 2 4 6 8 10
Years since diagnosis
Figure 15  Partitioning of the crude probability space of cancer patients
Furthermore, we derive and discuss the usefulness of conditional crude probabilities as a tool for
supplying patients with updated estimates of their anticipated prognosis.
9.2 Data
All cases of malignant melanoma (ICD7: 190x), colon cancer (ICD7: 153x) and acute myeloid
leukemia (AML)(ICD7: 205.0, 205.9, 206.0 and 206.9) diagnosed in Sweden between 1973 and
2007, at ages 19 to 80, were extracted from the Swedish Cancer Register. Information about date
of death for deceased individuals was retrieved from the Swedish Causes of Death Register. No
4Even though the term 'personal cure' has been introduced in a population-based setting previously, using a
grouped data approach [94], we have deliberately avoided to use this terminology in the current study since it
provides a poor description of what is, in fact, estimated.
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patients were excluded on the basis of previous cancer diagnoses, although in patients with multiple
tumors of the same type, we only considered the ﬁrst diagnosis. Incidental autopsy ﬁndings and
benign cancers were excluded from each of the three cohorts (melanoma: 11,958 exclusions, colon
cancer: 14,517 exclusions, AML: 2,436 exclusions). The last observable date for administrative
follow-up was December 31, 2012.
9.3 Methods
The general approach to estimating the quantities of interest in this study is outlined below:
1. Estimate the (net) survival from ﬂexible parametric cure models. This involves deﬁning a
point from which the patients are assumed to no longer experience excess mortality from the
diagnosed cancer. In this study, and for all three cancer types, statistical cure was assumed
to occur at 10 years after the cancer diagnosis.
2. Transform estimates of (net) survival from the ﬂexible cure model into crude probabilities of
death from cancer by evaluating:
Crc(t) =
∫ t
0
S∗(u)R(u)λ(u)du,
and
Cro(t) =
∫ t
0
S∗(u)R(u)h∗(u)du.
3. Estimate the asymptote, Pbtd,c, to the cancer-speciﬁc cumulative incidence function, Crc(t).
Due to the pre-speciﬁed time of cure, this asymptote corresponds to Pbtd,c = Crc(10), and
deﬁnes the proportion of patients who are bound to die from their diagnosed cancer, (i.e., one
minus the 'personal cure' proportion).
4. Calculate cumulative crude probabilities that patients who have not yet died (from any cause)
at time t after diagnosis will eventually die from cancer, Cralive,c(t), versus other causes,
Cralive,o(t), using:
Cralive,c(t) = Pbtd,c − Crcr,c(t) (29)
and
Cralive,o(t) = 1− Crcr,o(t)− Pbtd,c (30)
The above steps partition the crude probability space of cancer patients according to Figure 15.
The proportion of patients who will not die from cancer, conditioning on having survived until time
t, was calculated from:
Cro|alive(t) = 1−
Pbtd,c − Crc(t)
1− Crc(t)− Cro(t) (31)
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The stpm2 program in the Stata software was used to ﬁt the ﬂexible parametric cure model. We
wrote a post-estimation command that was subsequently used to estimate equations (29)-(31).
The numerical approximations of the integrals and the variances used to construct 95% conﬁdence
intervals were performed using the methods described in chapter 5.3.1 of this thesis.
9.3.1 Approach to modelling
For the melanoma and colon cancer cohorts, we ﬁtted ﬂexible parametric cure models with 6 df for
modelling the baseline cumulative excess hazard function (where the knots placed at the 0th, 20th,
40th, 60th, 80th, 95th and 100:th centiles of the distribution of the uncensored log survival times).
For the AML cohort, we added one more internal knot at 8 years after diagnosis because the last
internal knot would otherwise be placed too early during follow-up (at 4.1 years). It has been shown
that it is important to disperse the internal knots over the entire follow-up when applying ﬂexible
parametric cure models in order to achieve a good ﬁt to the data [64].
All models were adjusted for sex, year of diagnosis and age at diagnosis. The eﬀects of the continuous
variables were assumed non-linear and modeled using restricted cubic splines (using 4 df to represent
the eﬀect of age, and 3 df for the calendar eﬀect). Furthermore, the eﬀect of age and calendar year
were modeled time dependently (using 3 × 4 df and 3 × 3 df, respectively, for the time-dependent
eﬀects), and assumed to interact (using an additional 3 × 1 df for the interaction eﬀect).
9.4 Findings and discussion
To cure a cancer patient from her disease can be viewed as the ultimate goal in medical decision
making, and the ability to quantify the anticipated survival from the prospect of cure should have
high clinical value. Statistical cure models aim to estimate the proportion of cancer patients who will
not experience any excess mortality from their disease. However, the cure proportion is estimated
in the absence of competing causes of death, and as such, it does not represent the actual survival
patterns in a given cohort of cancer patients. In this study, we have shown how to recalculate
net survival, and the statistical cure proportion, from a ﬂexible parametric cure model into crude
survival probabilities, and a competing risks analogue to the cure proportion. In addition, we
have shown how the crude probability of still being alive after a diagnosis of cancer can be further
partitioned to estimate the proportion of patients who were alive and bound to die from their cancer,
versus alive and bound to die from other causes. Results from this analysis, presented for males
diagnosed with melanoma, colon cancer and AML, respectively, in Sweden in 2005, are summarized
in Figure 16. These are cancer types where statistical cure models have previously been applied to
Swedish data, but where competing risks were not taken into account in the analyses [95, 96, 97].
The interpretation of the results in the earlier studies was therefore somewhat diﬀerent. Similar to
other measures of net survival, the statistical cure proportion is an appropriate measure to evaluate
the progress of control activities, or improvements of cancer treatment. As such, it is also useful
for cancer patients, but in an indirect way. Crude estimates of survival reﬂect the survival patterns
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Figure 16  Crude probability of death from melanoma, colon cancer, and AML in Sweden among
males diagnosed in 2005.
that are actually observed. Given the increasing number of long-term cancer survivors, there is also
a need for statistical survival measures that are applicable under the realistic situation where other
causes than cancer may lead to the death of the patient. We believe that such measures are of a
more direct interest to cancer patients and physicians for the purposes of risk communication, but
also for scheduling follow-up visits to the clinic for long-term survivors.
Survival time from diagnosis is of great relevance to clinicians, researchers, and administrators, but is
less relevant to patients who have already survived some initial period. Mortality for many types of
cancer is highest in the months immediately following diagnosis, and consequently, survival estimates
from diagnosis will not be of great relevance to patients who have already survived a number of
months (or years). Of greater interest are so-called conditional survival probabilities; the estimated
future (crude) survival probability, conditional on having survived some initial period following
diagnosis. Conditional survival probabilities can be used to provide regular updates of the prognosis
and can provide critical information that may decrease anxiety associated with the diagnosis of
cancer, and help deal with feelings of uncertainty about the future. Baade and colleagues, for
example, state that:
"for patients who survive 1,3 and 5 years after diagnosis, access to updated information for each
point of their cancer recovery is important, providing scope for evidence-based optimism as they
progress on the survivor's journey" [98].
Conditional crude survival probabilities provide such information but have not been reported often
in practice. Figure 17 shows the age-speciﬁc conditional crude probabilities that patients who are
still alive one year and three years, respectively, after their diagnosis, will die from a cause unrelated
to their diagnosed cancer. For all three cancer types, a general improvement in prognosis follows
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from each additional year survived. For colon cancer and melanoma, nearly all patients who have
survived at least ﬁve years, irrespective of age at diagnosis, are predicted to die from some cause
unrelated to their cancer.
A potential criticism of the results presented in Figure 17 is related to how sensitive the results are
to the assumption that statistical cure has been reached after 10 years of follow-up. We strongly
suggest that ﬂexible cure models should only be used to model cancer survival in situations where
it is known that excess mortality (on a group level) does eventually reach zero. For all cancer types
included in this study, there have been previous reports about statistical cure. Even so, it is useful
to also consider the robustness of the results with respect to the assumption that is made about
the timing of statistical cure by bringing the point of cure further forward in time. In Figure 17
we have therefor also overlaid the results from such sensitivity analyses, where statistical cure was
instead assumed to have occurred after 11, 12 and 13 years after diagnosis. The results are very
close to those based on the assumption that cure was reached after 10 years.
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Figure 17  Estimated proportion of patients with melanoma, colon cancer and AML who are predicted
to die from causes other than their cancer, conditional upon having survived for one and ﬁve years,
respectively.
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10 Conclusions and discussion
The overall aim of this thesis has been to develop and apply statistical methods for presenting
population-based cancer survival statistics in a manner relevant for physicians and patients. In one
way or other, most statistical analyses of cancer patient data can probably be classed as relevant
for physicians and patients. For example, randomized clinical treatment trials are necessary to
evaluate the eﬃcacy of new treatments and, if the outcome is satisfactory, the new treatment will
beneﬁt future patients, so the study is relevant for patients in that sense. An observational study
that correlates survival of cancer patients with dietary habits can be relevant for patients if the
knowledge gained provides clues into the aetiology of the disease, and can be used as grounds for
nutritional recommendations that improve the well-being of the patients. Studies that evaluate the
eﬀectiveness of screening programmes are highly relevant for patients, since acceptance for, and
participation in, existing programmes can be crucial to get an early diagnosis and to reduce the
burden of cancer. All of these research questions would typically be investigated using survival
analysis in a net framework5. However, throughout this thesis, I have referred to methods that are
relevant for physicians and patients almost synonymously with methods that aim to predict the
prognosis after a diagnosis of cancer in the presence of competing risks. Such methods are suitable
to e.g., predict survival for newly diagnosed patients, and to balance the risk of death from cancer,
overall or from treatment-related complications, against the risk of death from causes unrelated to
the diagnosed cancer. By presenting results in a manner that is understandable for both health
care professionals and lay audiences, and by explaining under what assumptions the methods and
statistical analyses are valid, we believe that such methods can be of direct use in risk counselling
between patients and physicians.
All studies in this thesis include competing risks methodology. In my experience, a wider recognition
of situations when the statistical analysis needs to be made in the presence, as opposed to absence,
of competing risks is needed. To date, many tutorial papers have been written on this subject, but
the uptake of new methods in applied research is generally slow and there still seems to be much
confusion surrounding this topic amongst medical researchers. In part, this is probably due to a
more general lack of understanding of the theoretical quantities that are, in fact, estimated using
traditional methods for survival analysis.
10.1 What do we aim to estimate?
To help researchers, unacquainted with statistical methods for competing risks, decide what analysis
to do, and what quantities can be estimated, I have developed a decision-tree (see next page) that
can serve as an informal guide towards an appropriate analysis. In principle, the choice of survival
analysis depends on the target quantity of interest, in this example net or crude survival.
5By a net survival framework I include methods that aim to estimate (net) survival functions, hazard rates and/or
hazard ratios
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Whether the ﬁtted model actually provides a reasonable estimate of the target quantity depends on
the degree of systematic and random error that is inherent in the data, or arise in the estimation.
The ﬂowchart aims to explain under what conditions net (marginal), cause-speciﬁc and subdistri-
bution hazard rates can be estimated, and what type of research questions each of these constructs
is best suited to answer6.
Broadly speaking, net survival is the underlying quantity of interest in many epidemiological appli-
cations (e.g., in studies of disease aetiology, or studies that investigate the eﬀect of prognostic factors
on cause-speciﬁc survival). Under the assumption of conditional independence between the compet-
ing events there is a one-to-one relationship between net hazard rates and net survival (path 1 in
ﬂowchart). This assumption is not formally testable using the competing risk data, but if violated,
cumulative survival curves (i.e., Kaplan-Meier curves or relative survival curves) do not provide
unbiased estimates of net survival, and the estimated hazard rates lose their (net) interpretation.
Without the independence assumption, the hazard rates become cause-speciﬁc hazard rates which
quantify the event rate in the realistic situation where individuals might experience a competing
event before the target event (path 2 in ﬂowchart). That is, net hazard rates and cause-speciﬁc
hazard rates are technically estimated using the same statistical machinery, but the interpretation
of the estimated hazard, as one or the other, depends on whether the independence assumption can
be regarded satisﬁed or not. The cause-speciﬁc hazard rates (and rate ratios), nevertheless, still
carry information that can be used for statistical inference. In practice, most epidemiological stud-
ies that aim to investigate a research question that pertains to net survival are probably analysed
using cause-speciﬁc hazard rates, and not marginal hazard rates, since the former can always be
estimated.
Crude survival, on the other hand, is primarily used to assess the impact of some risk/prognostic
factor on a speciﬁc target event, in the real-world situation when competing events might preclude
the event of interest from occurring. Unfortunately, the cause-speciﬁc hazard rate for a single cause
has no exact mathematical relationship with the corresponding cause-speciﬁc crude cumulative sur-
vival (i.e., cause-speciﬁc cumulative incidence functions). Instead, there are two main approaches
to estimation of crude survival from a regression modelling perspective,
1. by estimating the cause-speciﬁc hazard (or the excess hazard) and the all-cause survival and
transforming them to the crude survival scale in a separate step using equation 8 (path 3a in
ﬂowchart).
2. by estimating the subdistribution hazard, e.g., using the Fine-Gray model, which has a one-to-
one correspondence to the cause-speciﬁc cumulative incidence function (path 3b in ﬂowchart).
In contrast to the estimation of net survival, the independence assumption is not required to achieve
a valid estimate of crude survival. Throughout this thesis, we have applied the ﬁrst approach to
estimation. The Fine-Gray model has not been used, or discussed, in this thesis previously but is a
6Systematic errors, such as confounding, selection-bias, recall bias etc, are not included in the ﬂowchart but must
of course also be considered in order for any study to be valid.
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commonly adopted approach to estimating crude survival. In fact, the Fine-Gray model is probably
the most commonly applied method for estimating crude survival. The main reasons why we have
not considered the Fine-Gray model in this thesis, despite it's wide use in applied research, include:
• We measure cancer-speciﬁc survival using relative survival, as opposed to cause-speciﬁc sur-
vival. The Fine-Gray model has not been adapted for relative survival.
• In addition to crude survival probabilities, we also studied excess hazard rate ratios as an
eﬀect measure for the association between certain covariates and net survival. For example,
in studies II and III we compared and contrasted the inﬂuence of age at diagnosis, sex, and
year of diagnosis, on the excess DCS mortality and remaining excess mortality respectively.
These were estimated from the same ﬂexible parametric model that gave the estimates of S(t)
and λ(t) that were subsequently used to calculate crude survival probabilities. Subdistribu-
tion hazard rate ratios, estimated from a Fine-Gray model have a diﬀerent interpretation, as
compared to excess hazard rate ratios, and cannot be used to answer research questions that
pertain to net survival.
• Our group has developed a range of statistical methods for population-based cancer patient
survival by extending ﬂexible parametric survival models. A nice feature of the methods
described in studies II and V, is that they are also ﬁtted within this modelling framework.
We hope that this fact increases the acceptability and the uptake of the methods in applied
research.
Study I can be viewed as a classical competing risks analysis (in a relative survival framework) with
the goal to quantify probabilities of death from prostate cancer whilst adjusting for the competing
risk mortality. Studies II-IV, on the other hand, extend existing competing risks methodology, by
adapting and applying it in a new setting, in order to provide additional insight into the anticipated
prognosis of cancer patients.
For example, partitioning of excess mortality into component parts is conceptually similar to a cause-
speciﬁc competing risks analysis, where treatment related DCS deaths and other (non-treatment
related DCS) deaths are treated as separate outcomes. However, in practice, the fact that treatment
related DCS deaths are not possible to distinguish from DCS deaths that would have occurred
irrespective of whether the patient was treated or not, makes the analyses in studies II and II
impossible to carry out in a cause-speciﬁc setting. Thus, carrying over, and translating well-known
methods from the competing risks literature from a cause-speciﬁc to a relative survival framework
was needed.
Similarly, in study IV, we adapted competing risk methodology for relative survival to incorporate
the assumption that a proportion of the patients will eventually be statistically cured from their
disease. Such adaptation enabled estimation of "personal cure", and further partitioning of alive
cancer patients into distinct groups, based on their risk of eventually dying from the diagnosed
cancer, or from some cause unrelated to their disease. Summary measures of cancer patient survival
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that incorporate the prospect of cure are rarely reported, but can be useful in the dialogue between
physician and patient since it puts the health risks, faced by the patients with a curable cancer, in
context.
10.2 Presentation of results
With the development of new statistical methods, aimed at producing survival statistics that de-
scribe the likely outcome of a given disease, come challenges related to the presentation of the results
from such analyses.
In epidemiological association studies, there are often one or two variables (and possibly the in-
teraction between the two) whose eﬀect on the outcome is of main interest. However, additional
covariates are typically also included in the analyses to control for potential confounding. The
results of such studies are often quite easily summarized in terms of hazard ratios in tabular for-
mat. In studies aimed at prediction, more complex/larger statistical models are typically required
in order to give meaningful predictions. In principle, any pertinent data useful for predicting the
outcome should be considered in predictive models, although attention must also be paid to avoid
overﬁtting. In practice, at least when it comes to register-based studies, we use the data that we
have at hand for prediction. In the majority of the studies in this thesis, the data available were
those recorded in the Swedish Cancer Register. This limited the covariates available for analysis to
relatively basic demographic data about the patient (age at diagnosis, sex, year of diagnosis etc.),
and hardly any data related to the tumour or treatment (except in study I where data from the
NPCR were used). Even so, when continuous covariates were modelled continuously, as opposed
to categorically (which seems to be the tradition in epidemiology) the number of possible covariate
patterns grew quickly, even with as few as 3-4 predictors in the model. A structured presentation
of results becomes still harder when considering conditional estimates of survival, since updated
predictions should probably be calculated for several time points after diagnosis in order to have
value in a clinical setting. In order to comply with the space limitations set up by the scientiﬁc jour-
nals in which our studies were published, we focussed on demonstrating the statistical methods and
thus restricted the presentation of results to "typical" patients. New modes/formats for displaying
predictions are needed for a more exhaustive presentation of results from studies of this type, a fact
that has also been addressed by researchers at the Norwegian Cancer Registry as follows:
Providing realistic, relevant and accurate prognostic information on smaller groups conditioned on
follow-up time, stratiﬁed on age, stage and possibly other prognostic variables, will be challenging
and expand the traditional cancer registry reports, probably beyond the comfort zone [99].
There are several large ongoing projects to make cancer patient survival estimates accessible to
health care professionals and patients via online prognostic resources. These prediction tools aim to
provide individual-level predictions of, e.g., metastatic progression, cause-speciﬁc survival and/or
life expectancy, based on a proﬁle of values of prognostic factors that are entered into the web-based
application by the user. Predictions from elaborate statistical models are stored in a data base and
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shown only for the patient proﬁle that is asked for in a given search query. Examples of such work
include the Cancer Survival Query System (CSQS) [100], developed by the Division of Cancer Con-
trol and Population Sciences at the National Cancer Institute, the prediction resource developed
and published by the Memorial-Sloan Kettering Cancer Center [101], as well as PREDICT, an on-
line prediction resource for breast cancer survival, developed by the National Institute for Health
Research and the University of Cambridge [102]. Similar large scale programs do not yet exist
in Sweden, but seem like the logical next step to assist physicians in risk counselling and to help
their patients to better understand the prognosis and the risks and beneﬁts of various treatment
strategies.
10.3 Statistics targeted towards lay audiences
A reasonable question to ask is if we should be producing prognostic statistics aimed towards
patients at all, given the impossible task to foresee the future of an individual patient. It must
also be recognised that not all patients wish to speculate about their prognosis, and that physicians
might (quite rightly so) be reluctant to quote a single number that serves as a best guess of the
predicted prognosis. At the same time, information of this type is already communicated in the
clinics, although in more subtle terms than actual percentages, and patients and their families
are already known to actively search for information about their disease from web-based resources
[19, 103, 104]. To meet their information needs, whether it is to assemble an information base
for risk counselling, or to increase the general understanding of the potential implications of the
disease and treatment for the aﬀected patient/family member, we believe they should have access
to the most recent and relevant data. We are, however, not suggesting that observational data and
prognostic information from prediction tools of the type discussed above should be used in isolation,
but rather as a complement to other scientiﬁc reports, and the clinical judgement and experience
of the treating physician.
There is a vast amount of research and literature available on the topic of best practices for reporting
medical information to lay people, see for example [16, 14, 105]. When it comes to presenting data,
it is crucial to understand that patients are heterogeneous with respect to their information literacy,
numeracy, and susceptibility to framing eﬀects. In order to convey a clear message, all eﬀorts to make
data publicly available via e.g., web-based prediction tools must therefore be appropriately targeted
and adapted for the intended end-user. For example, visual tools that use natural frequencies to
display information have been found preferable to probability/percentage statements, or relative risk
measures that are quoted without reference to the absolute risks [106]. Another issue that needs to
be carefully explained when patients are seeking information outside the health care system, is the
distinction between single event probabilities and probabilities applicable on a group level [107]. For
this, we strongly advocate the use of disclaimers that explain the conditions for interpretation, and
that a complete picture for the individual patient is best given by the patients own care provider.
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11 Future perspectives
The opportunities to make more eﬃcient use of the internationally acclaimed health registers that
we have in Sweden are great. The Swedish cancer quality registers are starting to become mature,
and to reach a high level of completeness. It seems timely to review what information physicians,
who initiated and continuously report to these registers, wish to be able to access and bring into
their daily clinical work. With this thesis, we hope to have given some new ideas of how population-
based cancer register data could be used to investigate clinically relevant research questions, and to
summarise cancer patient survival statistics. My hope is that the work described can inspire new
work in the direction of making cancer patient survival statistics accessible to a broader range of
users. In addition to further tailoring cancer patient survival statistics to meet the needs of the
end users, and initiating the work towards developing a query system for presenting information
on cancer patient survival, a couple of methodological issues that require additional research are
described in this chapter.
11.1 Adjusting for comorbidities in studies of cancer patient survival
Relative survival is calculated as the ratio of the all-cause survival of the patients to the expected
survival of a comparable cohort from the general population, assumed free from the disease under
investigation. Apart from sex and calendar year, the expected survival is typically matched on each
patient's chronological age. However, adjusting for these factors alone might not be suﬃcient to
make the patients exchangeable to the general population. For example, among men with localised
prostate cancer we found than those who were diagnosed with low risk disease had, on average,
better all-cause survival than expected (i.e. negative excess mortality). One explanation for this
phenomenon is that the "biological age" of men with localised prostate cancer might, in fact, be lower
than their chronological age. The presence of comorbidities aﬀects the biological age of individuals,
yet comorbidities are very rarely considered in population-based studies of cancer patient survival.
When comorbidities are considered, the Charlson comorbidity index [108] is typically used. The
Charlson comorbidity index was developed to predict one-year all-cause mortality among patients
enrolled in clinical trials and may therefore not be optimal for studying long-term cancer patient
survival. An alternative approach to adjusting for comorbidities in cancer survival studies has
been proposed by researchers at the National Cancer Institute, and involves matching patients to a
reference population based also on the "biological"/health status adjusted age [100]. Determining an
individual patient's health status adjusted age was done by using the number and type of comorbid
conditions recorded in a national social insurance programme (Medicare). In this example the
investigators chose to include 15 conditions that are also included in the Charlson comorbidity
index, but in principle any combination of conditions can be included in the modelling of the health
status adjusted age. In Sweden, it would be possible to use data recorded in the in- and out-
patient hospital registers, but possibly also the Prescribed Drug Register, to identify the comorbid
conditions that have the strongest inﬂuence on the patients' "biological" age.
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A second approach to making cancer patients exchangeable to general population is to stratify the
conventionally used population mortality ﬁles on additional factors. US life tables are, for example,
often stratiﬁed on race, but suggestions and examples of population mortality ﬁles that include
social class, geographic region and smoking status also exist [109, 110, 95, 111]. Irrespective of
the preferred approach, to develop and apply methods that allow adjusting for additional factors
which make patients heterogeneous from the general population is important to further improve
predictions of survival in population-based cancer studies.
11.2 Assumptions for the expected survival in the cancer-free population
Standard errors of relative survival ratios are calculated without taking random variation in the
expected survival into consideration. Variation in the expected survival has generally been viewed
as negligible since the population life tables, from which the expected survival is typically retrieved,
are derived from a large sample (the entire population). The expected survival in a given cohort of
patients is, however, still subject to random variation resulting from random variation in the age
distribution of the cancer patients. Moreover, the random variation in the observed and expected
survival of cancer patients may be positively correlated, as both tend to decrease with increasing age.
Brenner and Hakulinen demonstrated empirically that the latter correlation was of such magnitude
that standard errors that accounted for the covariance between observed and expected survival were
generally lower than those standard errors that are conventionally used (and which entirely ignore
expected variation in relative survival calculations) [112]. In practice, this ﬁnding has not had an
inﬂuence on how standard errors for relative survival survival are calculated. Reasons for this might
be that the well-known Greenwood method at least gives conservative estimates of the standard
error, and that bootstrap conﬁdence intervals are found too computationally intensive in practice.
In this thesis, we have also relied on the assumption that any random variation in the expected
survival/mortality is negligible, and have treated them as ﬁxed in the estimation and calculation of
crude survival probabilities. A theoretical extension that is warranted involves assessing the validity
of this assumption. In particular, such evaluation is important if there is a general movement in
the ﬁeld towards stratifying population life tables on additional factors, such as socio-economic
status, race and/or comorbidity indices to satisfy the exchangeability assumption. Increasing the
dimension of population life tables inevitably also makes the argument that the variability in the
expected survival is negligible less convincing (since the data that gave rise to the life tables become
more sparse). Seppä et al. have recently studied the impact of treating region-speciﬁc expected
mortality rates as random quantities, as opposed to ﬁxed, in the context of quantifying region-
speciﬁc cure proportions among patients with colon cancer in Finland [113]. Only minor diﬀerences
in the estimated cure proportions and median survival times of the uncured were seen when the
expected mortality rates were treated as random. Studies that investigate the consequences of
treating expected mortality rates as ﬁxed in the settings of other cancer types and study designs
are, however, still needed.
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